: The AMEDEO Literature Guide

Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Liver Diseases

Free Subscription

Articles published in Hepatology
Retrieve available abstracts of 646 articles:
HTML format

Single Articles

March 2026

ZHANG D, Abulitipu A, Pang P, Bai L, et al
ECM1 protects against liver steatosis through PCBP1-mediated iron homeostasis.
Hepatology. 2026;83:603-622.
PubMed Abstract available

VAN KLEEF LA, Pustjens J, Schattenberg JM, Holleboom AG, et al
Comparison of diagnostic accuracy and utility of non-invasive tests for clinically significant liver disease in a general population with metabolic dysfunction.
Hepatology. 2026;83:591-602.
PubMed Abstract available

PIROLA CJ, Diambra L, Fernandez Gianotti T, Castano GO, et al
Organ damage proteomic signature identifies patients with MASLD at risk of systemic complications.
Hepatology. 2026;83:623-638.
PubMed Abstract available

SCHWIMMER JB, Thai NQN, Noon SL, Ugalde-Nicalo P, et al
Long-term mortality and extrahepatic outcomes in 1096 children with MASLD: A retrospective cohort study.
Hepatology. 2026;83:561-574.
PubMed Abstract available

QI X, Li J, Caussy C, Teng GJ, et al
Epidemiology, screening, and co-management of type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease.
Hepatology. 2026;83:661-678.
PubMed Abstract available

MA X, Niu M, Ni HM, Ding WX, et al
Mitochondrial dynamics, quality control, and mtDNA in alcohol-associated liver disease and liver cancer.
Hepatology. 2026;83:639-660.
PubMed Abstract available

February 2026

MASSOUDI D, Srivastava A, Dhanasekaran R
Unraveling the Tapestry: Lessons from multiomics and spatial biology in hepatocellular cancer.
Hepatology. 2026 Feb 12. doi: 10.1097/HEP.0000000000001716.
PubMed Abstract available

WEI JX, Lv LH, Wan YL, Cao Y, et al
Erratum: Vps4A functions as a tumor suppressor by regulating the secretion and uptake of exosomal microRNAs in human hepatoma cells.
Hepatology. 2026 Feb 5. doi: 10.1097/HEP.0000000000001667.
PubMed

LEUNG KK, Li W, Hansen B, Gulamhusein A, et al
Understanding hepatopancreatobiliary cancer risks in a population-based primary sclerosing cholangitis-inflammatory bowel disease cohort.
Hepatology. 2026 Feb 4. doi: 10.1097/HEP.0000000000001692.
PubMed Abstract available

YANG X, Yang N, Cheng Z, Zhang R, et al
Hepatic GPR75 exacerbates MASH through GNAI2-Dependent signaling.
Hepatology. 2026 Feb 3. doi: 10.1097/HEP.0000000000001706.
PubMed Abstract available

HU X, Zhang Q, Wan L, Liu M, et al
Letter to the editor: Hepatocyte-derived extracellular vesicles promote endothelial pyroptosis in chronic liver disease: Undefined role of miR-153-3p.
Hepatology. 2026 Feb 2. doi: 10.1097/HEP.0000000000001702.
PubMed

CHOI J, Xu J, Nguyen VH, Przybyszewski E, et al
Association between statin use and hepatic decompensation in patients with primary biliary cholangitis: A target trial emulation study.
Hepatology. 2026 Feb 2. doi: 10.1097/HEP.0000000000001701.
PubMed Abstract available

ALLEN AM, Kim WR, Carrieri P, Canning R, et al
Population perspectives on benefits and harms of screening for metabolic dysfunction-associated steatotic liver disease.
Hepatology. 2026;83:362-373.
PubMed Abstract available

ERICKSON H
Fueling fibrosis: The PBX1-IL7R axis and its role in hepatic stellate cell activation.
Hepatology. 2026;83:197-198.
PubMed

NG WH, Yeo YH, Kim H, Seki E, et al
Renin-angiotensin-aldosterone system inhibitor use improves clinical outcomes in patients with metabolic dysfunction-associated steatotic liver diseases: Target trial emulation using real-world data.
Hepatology. 2026;83:333-343.
PubMed Abstract available

ZHANG P, Liu D, Wu L, Wu X, et al
Neutrophil serine proteases NE and PR3 controlled by the miR-223/STAT3 axis potentiate MASH and liver fibrosis.
Hepatology. 2026;83:317-332.
PubMed Abstract available

CIRIACI N, Bertin L, Rautou PE
Genetic predisposition to porto-sinusoidal vascular disorder.
Hepatology. 2026;83:409-424.
PubMed Abstract available

January 2026

YANG J, Hwang Y, Ju JS, Han S, et al
Impact of newer antihyperglycemic agents on hepatic complications: A systematic review and meta-analysis of data from 5.3 million patients with type 2 diabetes mellitus.
Hepatology. 2026 Jan 29. doi: 10.1097/HEP.0000000000001695.
PubMed Abstract available

YAMAZOE T, Kakazu E, Matsuda M, Mino M, et al
Genomic and transcriptomic profiling of hepatocellular carcinoma in patients with Fontan-associated liver disease.
Hepatology. 2026 Jan 26. doi: 10.1097/HEP.0000000000001693.
PubMed Abstract available

YAMAMOTO S, Kodama T, Kuwano A, Maesaka K, et al
NRF2-COX2-PGE2 axis drives immune cold tumors and predicts resistance to combination immunotherapy in hepatocellular carcinoma.
Hepatology. 2026 Jan 15. doi: 10.1097/HEP.0000000000001677.
PubMed Abstract available

DING W, Wu J, Dou J, Liu F, et al
Biologically explicable multimodal model predicting local tumor progression and tumor invasiveness of hepatocellular carcinoma.
Hepatology. 2026 Jan 15. doi: 10.1097/HEP.0000000000001678.
PubMed Abstract available

WANG JJ, Lee YT, Kim AK, Villauneva A, et al
Clinical utilization of testing for cell-free DNA in hepatocellular cancer.
Hepatology. 2026 Jan 14. doi: 10.1097/HEP.0000000000001676.
PubMed Abstract available

ALLAIRE M, Bargellini I
Hepatocellular carcinoma with macrovascular invasion : Navigating heterogeneous evidence.
Hepatology. 2026 Jan 14. doi: 10.1097/HEP.0000000000001679.
PubMed

ZHANG VX, Suoangbaji T, Tsui YM, Sze KM, et al
Repurposing resmetirom suppresses MASH-associated hepatocellular carcinoma, with mechanistic implications of MDK/LRP1-mediated metabolic reprogramming and immunosuppression.
Hepatology. 2026 Jan 12. doi: 10.1097/HEP.0000000000001675.
PubMed Abstract available

WANG W, Yin S, Xu Q, Song D, et al
Biologically interpretable deep learning-derived MRI phenotypes reveal lymph node involvement and neoadjuvant therapy response in intrahepatic cholangiocarcinoma.
Hepatology. 2026 Jan 12. doi: 10.1097/HEP.0000000000001671.
PubMed Abstract available

HAZARI Y, Habbouche L, Garcia Lopez VA, Urra H, et al
Targeting the ER stress sensor IRE1 protects the liver from fibrosis through the downregulation of the proteostasis factor P4HB/PDIA1.
Hepatology. 2026;83:75-93.
PubMed Abstract available

PANAGIOTOPOULOS N, Wolfson T, Harris DT, Batakis D, et al
Proton density fat fraction for diagnosis of metabolic dysfunction-associated steatotic liver disease.
Hepatology. 2026;83:127-141.
PubMed Abstract available

KOH B, Xiao J, Ng CH, Law M, et al
Comparative efficacy of pharmacologic therapies for MASH in reducing liver fat content: Systematic review and network meta-analysis.
Hepatology. 2026;83:117-126.
PubMed Abstract available

CARLINI LE, Fernandez AC, Mellinger JL
Sex and gender in alcohol use disorder and alcohol-associated liver disease in the United States: A narrative review.
Hepatology. 2026;83:178-194.
PubMed Abstract available

HARRISON SA, Dubourg J, Knott M, Colca J, et al
Hyperinsulinemia, an overlooked clue and potential way forward in metabolic dysfunction-associated steatotic liver disease.
Hepatology. 2026;83:169-177.
PubMed Abstract available

WILECHANSKY RM
Breaching the blood-brain barrier: Functional MRI changes in covert hepatic encephalopathy.
Hepatology. 2026;83:4-5.
PubMed

KHAN S
PSC and HCC: Age and cirrhosis draw the line on risk.
Hepatology. 2026;83:1.
PubMed

December 2025

KORATALA A, Argaiz ER
Nuances in POCUS-guided hemodynamic assessment in cirrhosis.
Hepatology. 2025 Dec 17. doi: 10.1097/HEP.0000000000001648.
PubMed

PREMKUMAR M, Kajal K
Reply to 'Nuances in POCUS-guided hemodynamic assessment in cirrhosis'.
Hepatology. 2025 Dec 17. doi: 10.1097/HEP.0000000000001653.
PubMed

LI L, Fang Y, Zhang J, Song M, et al
Myeloid CD36 deficiency alleviates hepatic fibrosis by promoting adaptive immunity of macrophage.
Hepatology. 2025 Dec 16. doi: 10.1097/HEP.0000000000001646.
PubMed Abstract available

FORTUNY M, De Rosa A, Roca I, Ouchi D, et al
Hepatocellular carcinoma with macrovascular invasion: Review and survival meta-analysis of initial local therapy using minimal prognostic criteria.
Hepatology. 2025 Dec 15. doi: 10.1097/HEP.0000000000001630.
PubMed Abstract available

JI J, Chen Z, He W, Chen Y, et al
CXCR6 defines a distinct resident state in gammadelta T cells for protecting from liver cirrhosis.
Hepatology. 2025 Dec 11. doi: 10.1097/HEP.0000000000001643.
PubMed Abstract available

XUN Z, Wang H, Xuan Z, Xiong K, et al
Spatiotemporal landscape of intrahepatic cholangiocarcinoma liver metastasis at the single-cell level.
Hepatology. 2025 Dec 10. doi: 10.1097/HEP.0000000000001641.
PubMed Abstract available

RUAN Q, Chen T, Kim M, Yang H, et al
An alpha-specific PI3K inhibitor improves chemotherapy efficacy by inhibiting hepatic stellate cell activation in liver cancer.
Hepatology. 2025 Dec 8. doi: 10.1097/HEP.0000000000001639.
PubMed Abstract available

WANG X, Zhou Y, Zhang S, Farrar C, et al
Targeting mTORC2-Dependent AKT/FOXO1/RNF125 signaling exploits a therapeutic vulnerability in c-MET-activated and beta-catenin-mutated hepatocellular carcinoma.
Hepatology. 2025 Dec 2. doi: 10.1097/HEP.0000000000001637.
PubMed Abstract available

PINTO E VAIRO F, Zimmermann MT, Wagenknecht J, Jorge SD, et al
Discovery of a MET -driven monogenic cause of steatotic liver disease.
Hepatology. 2025;82:1512-1522.
PubMed Abstract available

November 2025

ZAPATA-PAVAS LE, Serrano-Macia M, Merlos Rodrigo MA, Barrenechea-Barrenechea JA, et al
NEDD8-specific protease 1 deficiency as a novel driver of hepatoblastoma development through dysregulation of the CAND1-NEDD8 pathway.
Hepatology. 2025 Nov 14. doi: 10.1097/HEP.0000000000001614.
PubMed Abstract available

HUANG X, Zhu T, Li S, Liu T, et al
Development and validation of a non-invasive score for at-risk metabolic dysfunction-associated steatohepatitis in individuals with obesity undergoing bariatric surgery.
Hepatology. 2025 Nov 13. doi: 10.1097/HEP.0000000000001612.
PubMed Abstract available

MULIAWAN GK, Lee TKW
Metabolic reprogramming in macrophages: A glutamine rescue in beta-catenin mutant hepatocellular carcinoma.
Hepatology. 2025 Nov 13. doi: 10.1097/HEP.0000000000001619.
PubMed

ZHAO J, Hou L, Dery KJ, Yuan X, et al
Hepatic ischemia reperfusion injury: Underlying mechanisms and concepts in liver surgery and liver transplantation.
Hepatology. 2025 Nov 11. doi: 10.1097/HEP.0000000000001609.
PubMed Abstract available

EL-KHOUEIRY AB, Kim RD, Harris WP, Sung MW, et al
A multicenter dose-defining/expansion phase 1b study of first-line regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma.
Hepatology. 2025 Nov 10. doi: 10.1097/HEP.0000000000001585.
PubMed Abstract available

JIANG Y, Li Y, Wu T, Cao L, et al
GPC3-based circular RNA vaccine suppresses hepatocellular carcinoma progression by activating adaptive immune responses.
Hepatology. 2025 Nov 7. doi: 10.1097/HEP.0000000000001605.
PubMed Abstract available

BANSAL MB, Patton H, Morgan TR, Carr RM, et al
Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: November 2025 updates to AASLD Practice Guidance.
Hepatology. 2025 Nov 7. doi: 10.1097/HEP.0000000000001608.
PubMed Abstract available

HUA H, Wang D, He L, Chen N, et al
KLF9 drives intermittent hypoxia-induced NAFLD by suppressing the NR4A1-p38 MAPK hepatic metabolic axis.
Hepatology. 2025 Nov 4. doi: 10.1097/HEP.0000000000001606.
PubMed Abstract available

LEI Z, Wu Y, Xue W, Zhu D, et al
Epigenetic repression of hepatocyte FoxO1 disrupts local immune homeostasis and promotes liver inflammation.
Hepatology. 2025 Nov 4. doi: 10.1097/HEP.0000000000001590.
PubMed Abstract available

HARTMANN P, Mouzaki M, Hassan S, Kehar M, et al
Call to action-Pediatric MASLD requires immediate attention to curb health crisis.
Hepatology. 2025;82:1341-1351.
PubMed Abstract available

WANG L, Dong W, Fan L, Kong H, et al
Repression of the ERRgamma-CYP2E1 pathway by FGF4 mitigates alcohol-associated liver injury.
Hepatology. 2025;82:1138-1154.
PubMed Abstract available

SERPER M, Tang H, Zhang S, McCullough A, et al
Clinical outcomes and care for spontaneous bacterial peritonitis: A national cohort study.
Hepatology. 2025;82:1187-1197.
PubMed Abstract available

ROUSSEAU D, Bonnafous S, Soysouvanh F, Sarrail D, et al
CD44 in myeloid cells is a major driver of liver inflammation and injury in alcohol-associated liver disease.
Hepatology. 2025;82:1211-1228.
PubMed Abstract available

NEWTON KP, Jayasekera D, Blackford AL, Behling C, et al
Longitudinal response to standard of care in pediatric metabolic dysfunction-associated steatotic liver disease: Rates of improvement and worsening, and factors associated with outcomes.
Hepatology. 2025;82:1198-1210.
PubMed Abstract available

UNALP-ARIDA A, Ruhl CE
Prevalence of metabolic dysfunction-associated steatotic liver disease and fibrosis defined by liver elastography in the United States using National Health and Nutrition Examination Survey 2017-March 2020 and August 2021-August 2023 data.
Hepatology. 2025;82:1256-1273.
PubMed Abstract available

NOUREDDIN M
MASH clinical trials and drugs pipeline: An impending tsunami.
Hepatology. 2025;82:1325-1340.
PubMed Abstract available

WANG X, Zhang L, Dong B
Molecular mechanisms in MASLD/MASH-related HCC.
Hepatology. 2025;82:1303-1324.
PubMed Abstract available

KHALID MB, Ilyas SI
Surgical resection for hepatocellular carcinoma: Leave no TACE?
Hepatology. 2025;82:1039-1040.
PubMed

October 2025

WEI T, Ma ZJ, Guo S, Weiss M, et al
Satellite lesions versus intrahepatic metastasis in multifocal intrahepatic cholangiocarcinoma: Prognostic impact and genomic profiling.
Hepatology. 2025 Oct 30. doi: 10.1097/HEP.0000000000001594.
PubMed Abstract available

HAN J, Zhao Y, Zhao J
Yttrium-90 superiority in hepatocellular carcinoma downstaging: Treatment effect or selection bias?
Hepatology. 2025 Oct 28. doi: 10.1097/HEP.0000000000001579.
PubMed

WALIA N, Hui S, Braude M
Letter to the Editor: Assessing HCC incidence and surveillance thresholds in non-cirrhotic MASLD.
Hepatology. 2025 Oct 23. doi: 10.1097/HEP.0000000000001586.
PubMed

GRIMAUD E, Gardin A, Ackermann O, Habes D, et al
Serum bile acid levels predict the development of portal hypertension and high-risk esophageal varices following successful Kasai in biliary atresia.
Hepatology. 2025 Oct 23. doi: 10.1097/HEP.0000000000001592.
PubMed Abstract available

DELGADO ER, Patel P, Tao J, Krutsenko Y, et al
Glutamine synthetase loss in beta-catenin-mutant hepatocellular carcinoma promotes tumor burden through macrophage metabolic reprogramming.
Hepatology. 2025 Oct 23. doi: 10.1097/HEP.0000000000001591.
PubMed Abstract available

JOHN BV, Bastaich D, Singal AG, Dahman B, et al
Reply: Assessing HCC incidence and surveillance thresholds in non-cirrhotic MASLD.
Hepatology. 2025 Oct 20. doi: 10.1097/HEP.0000000000001587.
PubMed

PATIDAR KR, Sharma P
Time to focus on POCUS For AKI management in cirrhosis.
Hepatology. 2025 Oct 16. doi: 10.1097/HEP.0000000000001583.
PubMed

ZHANG X, Gong H, Gu K, Chen D, et al
Letter to the Editor: Re-evaluating the clinical relevance of the RIPPLY1-TBX19 Axis in CTNNB1-Mutant hepatocellular carcinoma.
Hepatology. 2025 Oct 14. doi: 10.1097/HEP.0000000000001572.
PubMed

SALLMON H, Laufer G, Kurath-Koller S, Kramer P, et al
Letter to the editor: Esophageal varices in Fontan patients - circulatory or hepatic failure?
Hepatology. 2025 Oct 13. doi: 10.1097/HEP.0000000000001573.
PubMed

ABAD-JORDA L, Andres-Rozas M, Martinez-Alcocer A, Aspas J, et al
Hepatocyte-derived extracellular vesicles promote endothelial dedifferentiation in chronic liver disease through the miR-153-3p - pyroptosis axis.
Hepatology. 2025 Oct 10. doi: 10.1097/HEP.0000000000001567.
PubMed Abstract available

MA H, Zhang VX, Tsui YM, Lee JM, et al
Targeting sterol O-acyltransferase 1 rewires fatty acid metabolism and uncovers immune vulnerability in hepatocellular carcinoma.
Hepatology. 2025 Oct 9. doi: 10.1097/HEP.0000000000001561.
PubMed Abstract available

HUANG X, Lisman T
Cirrhotic portal vein thrombosis as a vascular rather than a thrombotic disorder.
Hepatology. 2025 Oct 8. doi: 10.1097/HEP.0000000000001565.
PubMed

ANTON A, Shalaby S, Botero ML, Blasi A, et al
Endothelial-to-mesenchymal transition: A targetable mechanism that contributes to portal vein thrombosis in cirrhosis.
Hepatology. 2025 Oct 6. doi: 10.1097/HEP.0000000000001547.
PubMed Abstract available

FOERSTER F, Wiesmann L, Bark P, Galle PR, et al
Pioneering precision: The evolution of immunotherapy for hepatocellular carcinoma.
Hepatology. 2025 Oct 2. doi: 10.1097/HEP.0000000000001554.
PubMed Abstract available

September 2025

WANG X, Luo J, Han L, Xu T, et al
FXR splicing by SF3B3 promotes MYC-driven hepatocarcinogenesis.
Hepatology. 2025 Sep 23. doi: 10.1097/HEP.0000000000001523.
PubMed Abstract available

PREMKUMAR M, Kajal K, Roy A, Izzy M, et al
'Point-of-Care Ultrasound (POCUS) guided volume management and the effect of cirrhotic cardiomyopathy on acute kidney injury outcomes in cirrhosis'.
Hepatology. 2025 Sep 23. doi: 10.1097/HEP.0000000000001524.
PubMed Abstract available

DELTENRE P, Marot A, Henrion J
A prognostic model in patients with alcohol-related cirrhosis does exist.
Hepatology. 2025 Sep 17. doi: 10.1097/HEP.0000000000001532.
PubMed

PAN Z
Letter to the editor: Technical considerations in the development of a multimodal deep learning model for predicting hepatocellular carcinoma outcomes.
Hepatology. 2025 Sep 17. doi: 10.1097/HEP.0000000000001534.
PubMed

LIU TH, Yang HC
Letter to the Editor: Clarifying the impact of response criteria and locoregional therapy on complete response outcomes in patients with hepatocellular carcinoma following immunotherapy.
Hepatology. 2025 Sep 4. doi: 10.1097/HEP.0000000000001459.
PubMed

ZHANG L, Li H, Zong W, Li B, et al
Letter to the Editor: Revisiting FOXP3 Expression and its prognostic implications in hepatocellular carcinoma.
Hepatology. 2025 Sep 3. doi: 10.1097/HEP.0000000000001512.
PubMed

HUANG CH, Ku WT, Wu TH, Lin PT, et al
Reply to the Letter to the Editor: Revisiting FOXP3 expression and its prognostic implications in hepatocellular carcinoma.
Hepatology. 2025 Sep 3. doi: 10.1097/HEP.0000000000001515.
PubMed

LAI JC, Tapper E, Tandon P
Integrative hepatology: Enhancing overall health to manage liver disease.
Hepatology. 2025 Sep 3. doi: 10.1097/HEP.0000000000001516.
PubMed Abstract available

JEONG JM, Choi SE, Shim YR, Kim HH, et al
CX3CR1+ macrophages interact with HSCs to promote HCC through CD8+ T-cell suppression.
Hepatology. 2025;82:655-668.
PubMed Abstract available

LI W, Chi Y, Xiao X, Li J, et al
Plasma FSTL-1 as a noninvasive diagnostic biomarker for patients with advanced liver fibrosis.
Hepatology. 2025;82:669-682.
PubMed Abstract available

YANG Y, Ni Q, Li H, Sun J, et al
Genomic and the tumor microenvironment heterogeneity in multifocal hepatocellular carcinoma.
Hepatology. 2025;82:582-598.
PubMed Abstract available

ZHOU KQ, Zhong YC, Song MF, Sun YF, et al
Distinct immune microenvironment of venous tumor thrombus in hepatocellular carcinoma at single-cell resolution.
Hepatology. 2025;82:566-581.
PubMed Abstract available

SINGAL AG, Quirk L, Boike J, Chernyak V, et al
Value of HCC surveillance in a landscape of emerging surveillance options: Perspectives of a multi-stakeholder modified Delphi panel.
Hepatology. 2025;82:794-809.
PubMed Abstract available

PANG Z, Zhang H, Zheng S, Yang X, et al
HNF4alpha-CDKL3 axis restricts MASLD progression by targeting FoxO1 via noncanonical phosphorylation.
Hepatology. 2025;82:702-721.
PubMed Abstract available

FACCIOLI LAP, Sun Y, Animasahun O, Motomura T, et al
Human-induced pluripotent stem cell-based hepatic modeling of lipid metabolism-associated TM6SF2-E167K variant.
Hepatology. 2025;82:638-654.
PubMed Abstract available

ERICKSON H
Hepatic stellate cells and macrophages: Key players in HCC immune suppression.
Hepatology. 2025;82:545-546.
PubMed

WILECHANSKY RM
Surging sludge: Intrahepatic cholangiocarcinoma mortality on the rise worldwide.
Hepatology. 2025;82:543-544.
PubMed

ZHANGYUAN G, Yu W, Tian W, Xie J, et al
RIPPLY1 suppresses cancer cell stemness via targeting TBX19 in CTNNB1-mutated hepatocellular carcinoma.
Hepatology. 2025 Sep 1. doi: 10.1097/HEP.0000000000001483.
PubMed Abstract available

SUN Y, Chen S, Xu X, Piao H, et al
Early on-treatment LSM reliably predicts liver-related events in CHB patients with significant fibrosis and cirrhosis.
Hepatology. 2025 Sep 1. doi: 10.1097/HEP.0000000000001504.
PubMed Abstract available

August 2025

HILSCHER MB
The pressure is on: Elucidating hemodynamic profiles associated with esophageal varices in the Fontan circulation.
Hepatology. 2025 Aug 26. doi: 10.1097/HEP.0000000000001510.
PubMed

ANANIA FA, Hager R, Higgins K, Makar GA, et al
Non-Invasive Tests: Establishing efficacy for metabolic dysfunction associated steatohepatitis beyond the biopsy-current perspectives from the division of hepatology and nutrition, US Food and Drug Administration.
Hepatology. 2025 Aug 26. doi: 10.1097/HEP.0000000000001509.
PubMed Abstract available

DING J, She HY, Cheng Y, Sun HY, et al
A novel mechanism involving USP53-regulated BSEP trafficking underlies low-GGT intrahepatic cholestasis.
Hepatology. 2025 Aug 19. doi: 10.1097/HEP.0000000000001501.
PubMed Abstract available

ZHOU SL, Yin D, Hu ZQ, Luo CB, et al
Erratum: A positive feedback loop between cancer stem-like cells and tumor-associated neutrophils controls hepatocellular carcinoma progression.
Hepatology. 2025 Aug 14. doi: 10.1097/HEP.0000000000001476.
PubMed

JOHN BV, Bastaich DR, Deng Y, Singal AG, et al
Use of liver stiffness measurement for hepatocellular carcinoma risk stratification in metabolic dysfunction associated steatotic liver disease.
Hepatology. 2025 Aug 14. doi: 10.1097/HEP.0000000000001498.
PubMed Abstract available

INDRE MG, Leucuta DC, Lupsor-Platon M, Turco L, et al
Diagnostic accuracy of 2D-SWE ultrasound for liver fibrosis assessment in MASLD: A multilevel random effects model meta-analysis.
Hepatology. 2025;82:454-469.
PubMed Abstract available

LOH JJ, Ng KY, Huang IB, Deng M, et al
DGKH-mediated phosphatidic acid oncometabolism as a driver of self-renewal and therapy resistance in HCC.
Hepatology. 2025;82:308-325.
PubMed Abstract available

DRIESSEN S, Francque SM, Anker SD, Castro Cabezas M, et al
Metabolic dysfunction-associated steatotic liver disease and the heart.
Hepatology. 2025;82:487-503.
PubMed Abstract available

SU T, Huang M, Liao J, Lin S, et al
Erratum: Insufficient radiofrequency ablation promotes hepatocellular carcinoma metastasis through N6-methyladenosine mRNA methylation-dependent mechanism.
Hepatology. 2025;82:E35-E36.
PubMed

July 2025

ACUNA-PILARTE K, Reichert EC, Green YS, Halberg LM, et al
Erratum: HAF prevents hepatocyte apoptosis and progression to MASH and HCC through transcriptional regulation of the NF-kappaB pathway.
Hepatology. 2025 Jul 30. doi: 10.1097/HEP.0000000000001416.
PubMed

FAN G, Han X, Shi Y
Reply: Reevaluating PCA and SCTransform usage in single-cell intrahepatic cholangiocarcinoma analysis.
Hepatology. 2025 Jul 30. doi: 10.1097/HEP.0000000000001480.
PubMed

TAKEFUJI Y
Letter to the editor: Reevaluating PCA and SCTransform usage in single-cell intrahepatic cholangiocarcinoma analysis.
Hepatology. 2025 Jul 29. doi: 10.1097/HEP.0000000000001479.
PubMed

APODAKA-BIGURI M, Simao AL, Gonzalez-Romero F, Mestre D, et al
E2F2 transcription factor promotes a cholestatic MASH phenotype by regulating hepatobiliary metabolism through miR-34a-5p.
Hepatology. 2025 Jul 28. doi: 10.1097/HEP.0000000000001461.
PubMed Abstract available

NAKIB D, MacParland S
Decoding the PSC fibrotic niche: Hepatocyte stress and metallothioneins.
Hepatology. 2025 Jul 25. doi: 10.1097/HEP.0000000000001478.
PubMed

HUANG Q, Wang W, Ge Q, Xu D, et al
NEK7 induced phosphorylation of EGFR on serine 1070 drive the acquired lenvatinib resistance in hepatocellular carcinoma.
Hepatology. 2025 Jul 22. doi: 10.1097/HEP.0000000000001474.
PubMed Abstract available

SEIF EL DAHAN K, Daher D, Rich NE, Nayak AJ, et al
Causes of mortality among patients with early-stage hepatocellular carcinoma.
Hepatology. 2025 Jul 22. doi: 10.1097/HEP.0000000000001471.
PubMed Abstract available

TELLEZ L, Toledano M, Alvarez M, Garrido-Lestache E, et al
Distinctive hemodynamic phenotype in Fontan-type circulation patients with distal esophageal varices.
Hepatology. 2025 Jul 22. doi: 10.1097/HEP.0000000000001472.
PubMed Abstract available

ABRUZZESE GA, Martinez-Chantar ML
Minor players, major signals: Unveiling the systemic and gut-localized impact of microbial amidated bile acids in hepatopancreatobiliary disease.
Hepatology. 2025 Jul 21. doi: 10.1097/HEP.0000000000001473.
PubMed

BAJAJ JS, Reddy KR, Tandon P, Lai JC, et al
Salivary microbiome and serum metabolomics add to clinical biomarkers to predict 6-month hospitalizations in a multi-center cirrhosis outpatient cohort.
Hepatology. 2025 Jul 9. doi: 10.1097/HEP.0000000000001462.
PubMed Abstract available

SCHEINER B, Pinter M
Reply: Clarifying the impact of response criteria and locoregional therapy on complete response outcomes in patients with hepatocellular carcinoma following immunotherapy.
Hepatology. 2025 Jul 7. doi: 10.1097/HEP.0000000000001460.
PubMed

SU TH, Shin EC
Peripheral blood Foxp3-High tregs: A novel prognostic biomarker in hepatocellular carcinoma.
Hepatology. 2025 Jul 7. doi: 10.1097/HEP.0000000000001464.
PubMed

SINHA S, Ali Q, Zhang T, T-Nguyen DH, et al
Aging disrupts hepatocyte zonation homeostasis in mice and humans.
Hepatology. 2025 Jul 4. doi: 10.1097/HEP.0000000000001451.
PubMed Abstract available

GUO Y, Zhang Q, Li B, Dai W, et al
Biliary YB-1/GLI2 axis facilitates ductular reaction and promotes hepatic stellate cell activation via SPP1/Integrin alphavbeta1 signaling during liver fibrogenesis.
Hepatology. 2025 Jul 4. doi: 10.1097/HEP.0000000000001458.
PubMed Abstract available

CHONG LUGON N, Rabiee A, Mezzacappa C, Kaplan DE, et al
Prognostic significance of mild ascites in patients with cirrhosis.
Hepatology. 2025 Jul 3. doi: 10.1097/HEP.0000000000001452.
PubMed Abstract available

TRAUNER M, Karpen SJ, Dawson PA
Benefits and challenges to therapeutic targeting of bile acid circulation in cholestatic liver disease.
Hepatology. 2025 Jul 2. doi: 10.1097/HEP.0000000000001438.
PubMed Abstract available

UNTALAN M, A Crimmins N, Yates KP, A Mencin A, et al
Prevalence of subclinical hypothyroidism and longitudinal thyroid-stimulating hormone changes in youth with metabolic dysfunction-associated steatotic liver disease: An observational study.
Hepatology. 2025;82:155-164.
PubMed Abstract available

SALIBA-GUSTAFSSON P, Justesen JM, Ranta A, Sharma D, et al
A functional genomic framework to elucidate novel causal metabolic dysfunction-associated fatty liver disease genes.
Hepatology. 2025;82:165-183.
PubMed Abstract available

HAI S, Li X, Xie E, Wu W, et al
Intestinal IL-33 promotes microbiota-derived trimethylamine N -oxide synthesis and drives metabolic dysfunction-associated steatotic liver disease progression by exerting dual regulation on HIF-1alpha.
Hepatology. 2025;82:184-198.
PubMed Abstract available

DIAZ LA, Winder GS, Leggio L, Bajaj JS, et al
New insights into the molecular basis of alcohol abstinence and relapse in alcohol-associated liver disease.
Hepatology. 2025;82:254-271.
PubMed Abstract available

ADLAT S, Vazquez Salgado AM, Lee M, Yin D, et al
Emerging and potential use of CRISPR in human liver disease.
Hepatology. 2025;82:232-253.
PubMed Abstract available

HUANG CH, Ku WT, Mahalingam J, Wu CH, et al
Tumor-migrating peripheral Foxp3-high regulatory T cells drive poor prognosis in hepatocellular carcinoma.
Hepatology. 2025 Jul 1. doi: 10.1097/HEP.0000000000001428.
PubMed Abstract available

XU X, Li H, Lin H, Li Q, et al
MIF-mediated crosstalk between THRSP+ hepatocytes and CD74+ lipid-associated macrophages in hepatic periportal zone drives MASH.
Hepatology. 2025 Jul 1. doi: 10.1097/HEP.0000000000001429.
PubMed Abstract available

June 2025

NAM H, Kim DY, Kim DY, Kim JH, et al
Development and validation of a risk prediction model for patients with hepatocellular carcinoma receiving atezolizumab-bevacizumab.
Hepatology. 2025 Jun 30. doi: 10.1097/HEP.0000000000001444.
PubMed Abstract available

ZHANG L, Han C, Shrestha MM, Le J, et al
The OGT-TFF2 axis mediates intrahepatic crosstalk and MASH pathogenesis.
Hepatology. 2025 Jun 30. doi: 10.1097/HEP.0000000000001445.
PubMed Abstract available

XIAOFANG S, Zhanhui O, Ruochan C, Xiaohua N, et al
Erratum: Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells.
Hepatology. 2025 Jun 25. doi: 10.1097/HEP.0000000000001384.
PubMed

LI J, Xu L, Rui F, Tran S, et al
Type 2 Diabetes mellitus as an independent predictor of significant fibrosis in treatment-naive chronic hepatitis B patients with concurrent hepatic steatosis.
Hepatology. 2025 Jun 25. doi: 10.1097/HEP.0000000000001442.
PubMed Abstract available

YANG DL, Ye L, Zeng FJ, Liu J, et al
Erratum: Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in
Hepatology. 2025 Jun 25. doi: 10.1097/HEP.0000000000001401.
PubMed

TEMPRANO AG, Romero MR, Ghallab A, Llera L, et al
Gut-to-Bile transfer of microbially amidated minor bile acids in patients with hepatopancreatobiliary disorders.
Hepatology. 2025 Jun 23. doi: 10.1097/HEP.0000000000001441.
PubMed Abstract available

TAO J, Wang J
Reply: Considerations on the specific role of LHX2 in the process of hepatic stellate cells regulating hepatocyte function.
Hepatology. 2025 Jun 18. doi: 10.1097/HEP.0000000000001435.
PubMed

NI J, Zhai D, Li J, Li B, et al
Letter to editor: Considerations on the specific role of LHX2 in the process of hepatic stellate cells regulating hepatocyte function.
Hepatology. 2025 Jun 16. doi: 10.1097/HEP.0000000000001434.
PubMed

SU JY, Li JR, Pan LX, Ma YL, et al
Tertiary lymphoid structures in hepatocellular carcinoma: Influence on immune cell profiles in tumors and on efficacy of adjuvant PD-1 inhibitor therapy after hepatectomy.
Hepatology. 2025 Jun 11. doi: 10.1097/HEP.0000000000001433.
PubMed Abstract available

SHAW J, Acharya C, Fagan A, Olofson A, et al
Health IT interventions reduce avoidable readmissions in cirrhosis: The HEROIC randomized controlled trial.
Hepatology. 2025 Jun 11. doi: 10.1097/HEP.0000000000001424.
PubMed Abstract available

LI F, Li Y, Wang L, Xu L, et al
Tumor microenvironment heterogeneity and progression mechanisms in intrahepatic cholangiocarcinoma: A study based on single-cell and spatial transcriptomic sequencing.
Hepatology. 2025 Jun 9. doi: 10.1097/HEP.0000000000001423.
PubMed Abstract available

PEDDU DK, Tedesco N, Rutledge SM, Wijarnpreecha K, et al
Social determinants of health influence the risk of cirrhosis: A diverse nationwide cohort study.
Hepatology. 2025 Jun 9. doi: 10.1097/HEP.0000000000001420.
PubMed Abstract available

BIAN Q, Wang S, Song Z, Liu F, et al
Arid1a deficiency promotes hepatocyte hyperpolyploidy and drives intrahepatic cholangiocarcinoma in mice.
Hepatology. 2025 Jun 9. doi: 10.1097/HEP.0000000000001422.
PubMed Abstract available

WANG H, Wang S, Lei Y, Chen Y, et al
Serum amyloid A1-Induced intrahepatic regulatory T cell dysfunction drives autoimmune hepatitis progression.
Hepatology. 2025 Jun 9. doi: 10.1097/HEP.0000000000001419.
PubMed Abstract available

MANDORFER M, Jachs M, Semmler G
Roadmap for a generally accepted model to predict first hepatic decompensation in compensated advanced chronic liver disease.
Hepatology. 2025 Jun 9. doi: 10.1097/HEP.0000000000001431.
PubMed

LIANG BG, Zheng YM, Xu MH, Gao C, et al
The MASTL/YBX1/PAK4 axis regulated by stress-activated STK24 triggers lenvatinib resistance and tumor progression in hepatocellular carcinoma.
Hepatology. 2025 Jun 2. doi: 10.1097/HEP.0000000000001392.
PubMed Abstract available

TINCOPA MA, Diaz LA, Huang DQ, Arab JP, et al
Disparities in screening and risk stratification for Hispanic adults with metabolic dysfunction-associated steatotic liver disease.
Hepatology. 2025;81:1792-1804.
PubMed Abstract available

MARINO Z, Garcia-Sola C, Rios J, Bono A, et al
Exchangeable copper for patients with Wilson disease at follow-up: Rethinking normal ranges or changing methodology.
Hepatology. 2025;81:1728-1739.
PubMed Abstract available

FAN L, Tian C, Yang W, Liu X, et al
HKDC1 promotes liver cancer stemness under hypoxia through stabilizing beta-catenin.
Hepatology. 2025;81:1685-1699.
PubMed Abstract available

BAKRANIA A, Mo Y, Zheng G, Bhat M, et al
RNA nanomedicine in liver diseases.
Hepatology. 2025;81:1847-1877.
PubMed Abstract available

MACHIDA K, Tsukamoto H, Liu JC, Han YP, et al
Retraction: C-Jun mediates hepatitis C virus hepatocarcinogenesis through signal transducer and activator of transcription 3 and nitric oxide-dependent impairment of oxidative DNA repair.
Hepatology. 2025;81:E181.
PubMed

JIANG JX, Fish SR, Tomilov A, Li Y, et al
Erratum: Nonphagocytic activation of NOX2 is implicated in progressive nonalcoholic steatohepatitis during aging.
Hepatology. 2025;81:E180.
PubMed

HARRIS K
LPCN 1148: Rebuilding muscle memory in cirrhosis patients.
Hepatology. 2025;81:1625-1626.
PubMed

EISWERTH M, Arab JP
A new voice in diagnosing and predicting hepatic encephalopathy.
Hepatology. 2025;81:1623-1624.
PubMed

May 2025

NGUYEN T, Shin Y, Ruppa A, Krall AS, et al
Galectin-1 modulates glycolysis via a GM1-galactose-dependent pathway to promote hyperthermia resistance in hepatocellular carcinoma.
Hepatology. 2025 May 21. doi: 10.1097/HEP.0000000000001391.
PubMed Abstract available

XIE L, Chen H, Zhang L, Yang YY, et al
Suppressing MASH fibrotic progression by blocking succinate-GPR91 signaling in hepatic stellate cells.
Hepatology. 2025 May 19. doi: 10.1097/HEP.0000000000001405.
PubMed Abstract available

REGHUPATY SC, Raha S, Mendoza R, Manna D, et al
TATA-box binding protein associated factor 2 (TAF2) in hepatocyte survival and tumorigenesis.
Hepatology. 2025 May 19. doi: 10.1097/HEP.0000000000001406.
PubMed Abstract available

LAU G, Sangro B, Cheng AL, Kudo M, et al
Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable hepatocellular carcinoma: HIMALAYA phase 3 randomized clinical trial.
Hepatology. 2025 May 16. doi: 10.1097/HEP.0000000000001385.
PubMed Abstract available

JIN Y, Wang M, Xu A, Xu B, et al
Letter to the Editor: Association between mean arterial pressure and terlipressin in the reversal of hepatorenal syndrome-acute kidney injury.
Hepatology. 2025 May 15. doi: 10.1097/HEP.0000000000001404.
PubMed

WANG Y, Yang L, Li M, Hao J, et al
Proenkephalin produced by neonatal T-bet+ Treg cells promotes periportal hepatocyte maturation.
Hepatology. 2025 May 12. doi: 10.1097/HEP.0000000000001389.
PubMed Abstract available

WANG C, Dong D, Zhao N, Zhao S, et al
Hepatocyte-specific C-C motif chemokine ligand 9 signaling promotes liver fibrosis progression in mice.
Hepatology. 2025 May 9. doi: 10.1097/HEP.0000000000001393.
PubMed Abstract available

YANG DL, Li YF, Li YJ, Qiu GG, et al
Reply: Survival benefit of transarterial chemoembolization combined with tyrosine kinase and immune checkpoint inhibitors as conversion therapy for unresectable hepatocellular carcinoma needs more details.
Hepatology. 2025 May 9. doi: 10.1097/HEP.0000000000001395.
PubMed

YU TC, Zhao L, Sze KM, Tian L, et al
GPD1L supports glycerol-3-phosphate and triacylglycerol synthesis and promotes tumor progression in hepatocellular carcinoma.
Hepatology. 2025 May 9. doi: 10.1097/HEP.0000000000001394.
PubMed Abstract available

GENG Y, Schwabe RF
Hepatic stellate cell heterogeneity: Functional aspects and therapeutic implications.
Hepatology. 2025 May 8. doi: 10.1097/HEP.0000000000001386.
PubMed Abstract available

O'ROURKE CJ, Andersen JB
Intrahepatic Cholangiocarcinoma PANoptosidy.
Hepatology. 2025 May 8. doi: 10.1097/HEP.0000000000001398.
PubMed

WANG D, Yi S, Liu X
Letter to the editor: Survival benefit of transarterial chemoembolization combined with tyrosine kinase and immune checkpoint inhibitors as conversion therapy for unresectable hepatocellular carcinoma needs more details.
Hepatology. 2025 May 8. doi: 10.1097/HEP.0000000000001390.
PubMed

YANG Z, Jiang Y, Ma J, Wang L, et al
LncRNA H19 promoted alcohol-associated liver disease through dysregulation of alternative splicing and methionine metabolism.
Hepatology. 2025;81:1485-1500.
PubMed Abstract available

SUN Y, Wei H, Yu W, Gao H, et al
The actin-binding protein drebrin disrupts NF2-LATS kinases complex assembly to facilitate liver tumorigenesis.
Hepatology. 2025;81:1433-1451.
PubMed Abstract available

ZHANG S, Yan Y, Zeng XF, Gu Y, et al
Associations of the EAT-Lancet reference diet with metabolic dysfunction-associated steatotic liver disease and its severity: A multicohort study.
Hepatology. 2025;81:1583-1594.
PubMed Abstract available

HUANG DQ, Wilson LA, Behling C, Amangurbanova M, et al
Liver stiffness progression in biopsy-proven metabolic dysfunction-associated steatotic disease among people with diabetes versus people without diabetes: A prospective multicenter study.
Hepatology. 2025;81:1553-1563.
PubMed Abstract available

OLUBAMIWA AO, Liao TJ, Zhao J, Dehanne P, et al
Drug interaction with UDP-Glucuronosyltransferase (UGT) enzymes is a predictor of drug-induced liver injury.
Hepatology. 2025;81:1512-1521.
PubMed Abstract available

MONIAUX N, Geoffre N, Deshayes A, Dos Santos A, et al
Tumor suppressive role of the antimicrobial lectin REG3A targeting the O -GlcNAc glycosylation pathway.
Hepatology. 2025;81:1416-1432.
PubMed Abstract available

NOVOA E, da Silva Lima N, Gonzalez-Rellan MJ, Chantada-Vazquez MDP, et al
Mitochondrial antiviral signaling protein enhances MASLD progression through the ERK/TNFalpha/NFkappabeta pathway.
Hepatology. 2025;81:1535-1552.
PubMed Abstract available

DE RUDDER M, Manco R, Coubeau L, Fontaine A, et al
Vascular damage and excessive proliferation compromise liver function after extended hepatectomy in mice.
Hepatology. 2025;81:1468-1484.
PubMed Abstract available

NORDEN-KRICHMAR TM, Rotroff D, Schwantes-An TH, Bataller R, et al
Genomic approaches to explore susceptibility and pathogenesis of alcohol use disorder and alcohol-associated liver disease.
Hepatology. 2025;81:1595-1606.
PubMed Abstract available

CHAGANTI J, Zeng G, Patil A, Lockart I, et al
Altered blood-brain barrier permeability is associated with abnormal distant connectivity and regional homogeneity in covert hepatic encephalopathy - a cross sectional study.
Hepatology. 2025 May 1. doi: 10.1097/HEP.0000000000001343.
PubMed Abstract available

ZHANG Q, Song Q, Liu Y, Li J, et al
Letter to the Editor: Redefining post-resection care: Critical analysis of adjuvant TACE in curative hepatocellular carcinoma management.
Hepatology. 2025 May 1. doi: 10.1097/HEP.0000000000001327.
PubMed

April 2025

YAO J, Liu P, Teng X, Kong D, et al
Alcohol-induced disruption of hepatic m6A modification exacerbates alcohol-associated steatohepatitis by impairing liver immune microenvironment homeostasis.
Hepatology. 2025 Apr 30. doi: 10.1097/HEP.0000000000001374.
PubMed Abstract available

FUJIWARA N, Matsushita Y, Tempaku M, Tachi Y, et al
AI-based phenotyping of hepatic fiber morphology to inform molecular alterations in metabolic dysfunction-associated steatotic liver disease.
Hepatology. 2025 Apr 22. doi: 10.1097/HEP.0000000000001360.
PubMed Abstract available

FIX OK, Kane M, Gainey CS, Khairat S, et al
Privacy and fidelity: The promise of synthetic data in hepatology research.
Hepatology. 2025 Apr 21. doi: 10.1097/HEP.0000000000001361.
PubMed

WANG J, Zhang S, Fan T, Wu C, et al
Letter to the Editor: Association of hepatitis B surface antigen and risk of hepatocellular carcinoma in chronic hepatitis B patients with immune-tolerant phase.
Hepatology. 2025 Apr 21. doi: 10.1097/HEP.0000000000001365.
PubMed

HUI VW, Wong GL, Dai J, Tse YK, et al
Increased risk of hepatocellular carcinoma in HBeAg-negative indeterminate phase compared to HBeAg-negative chronic infection.
Hepatology. 2025 Apr 21. doi: 10.1097/HEP.0000000000001354.
PubMed Abstract available

TSENG TC, Kao JH
Reply: Association of hepatitis B surface antigen and risk of hepatocellular carcinoma in chronic hepatitis B patients with immune-tolerant phase.
Hepatology. 2025 Apr 21. doi: 10.1097/HEP.0000000000001366.
PubMed

HOLMER M, Ingre M, Farkkila M, Ponsioen C, et al
Cirrhosis and age are key determinants of HCC risk in individuals with primary sclerosing cholangitis: A multicenter longitudinal cohort study.
Hepatology. 2025 Apr 16. doi: 10.1097/HEP.0000000000001351.
PubMed Abstract available

YU Y, You Y, Duan Y, Kang M, et al
Multiomics approaches for identifying the PANoptosis signature and prognostic model via a multimachine-learning computational framework for intrahepatic cholangiocarcinoma.
Hepatology. 2025 Apr 15. doi: 10.1097/HEP.0000000000001352.
PubMed Abstract available

ROCCARINA D, Saltini D, Senzolo M, Nardelli S, et al
Reply: Post-TIPS hemodynamic target adherence fails to improve outcomes in cirrhotic patients.
Hepatology. 2025 Apr 8. doi: 10.1097/HEP.0000000000001350.
PubMed

TANTAI X, Li L, Dai S
Letter to the editor: Considerations on the use of LPCN 1148 in cirrhotic patients with sarcopenia.
Hepatology. 2025 Apr 8. doi: 10.1097/HEP.0000000000001347.
PubMed

TANTAI X, Li L, Dai S
Letter to the editor: Post-TIPS hemodynamic target adherence fails to improve outcomes in cirrhotic patients.
Hepatology. 2025 Apr 8. doi: 10.1097/HEP.0000000000001349.
PubMed

BRUNO BJ, Weavil JC, Ogle J, Chidambaram N, et al
Reply: Considerations on the use of LPCN 1148 in cirrhotic patients with sarcopenia.
Hepatology. 2025 Apr 8. doi: 10.1097/HEP.0000000000001348.
PubMed

YANG LX, Gao Q, Shi JY, Wang ZC, et al
Erratum: Mitogen-activated protein kinase kinase kinase 4 deficiency in intrahepatic cholangiocarcinoma leads to invasive growth and epithelial-mesenchymal transition.
Hepatology. 2025 Apr 7. doi: 10.1097/HEP.0000000000001274.
PubMed

GOLDBERG D, Blandon C, Delgado C, John B, et al
Simulating the impact of survival benefit-based liver transplant organ allocation.
Hepatology. 2025 Apr 4. doi: 10.1097/HEP.0000000000001338.
PubMed Abstract available

LAI JC, Lok AS
Accurate prediction of hepatocellular carcinoma risk in patients with chronic HBV infection: HBeAg status and HBsAg level matter.
Hepatology. 2025 Apr 3. doi: 10.1097/HEP.0000000000001345.
PubMed

WANG B, Hsu SH, Wang X, Kutay H, et al
Erratum: Reciprocal regulation of microRNA-122 and c-Myc in hepatocellular cancer: Role of E2F1 and transcription factor dimerization partner 2.
Hepatology. 2025 Apr 3. doi: 10.1097/HEP.0000000000001261.
PubMed

NOBEL YR, Boike JR, Mazumder NR, Thornburg B, et al
Predictors of long-term clinical outcomes after TIPS: An ALTA group study.
Hepatology. 2025;81:1244-1255.
PubMed Abstract available

OJHA U, Kim S, Rhee CY, You J, et al
Endothelial RUNX3 controls LSEC dysfunction and angiocrine LRG1 signaling to prevent liver fibrosis.
Hepatology. 2025;81:1228-1243.
PubMed Abstract available

LEFERE S, Mosca A, Hudert C, Dupont E, et al
Development and validation of pFIB scores for exclusion of significant liver fibrosis in pediatric MASLD.
Hepatology. 2025;81:1276-1287.
PubMed Abstract available

HLADY RA, Zhao X, El Khoury LY, Wagner RT, et al
Epigenetic heterogeneity hotspots in human liver disease progression.
Hepatology. 2025;81:1197-1210.
PubMed Abstract available

STALLER DW, Panigrahi SS, Jayasinghe YP, Dong Y, et al
A novel phosphodiesterase inhibitor for the treatment of chronic liver injury and metabolic diseases.
Hepatology. 2025;81:1288-1303.
PubMed Abstract available

ZANUSO V, Rimassa L, Braconi C
The rapidly evolving landscape of HCC: Selecting the optimal systemic therapy.
Hepatology. 2025;81:1365-1386.
PubMed Abstract available

KUREBAYASHI Y, Sakamoto M
Macrotrabecular hepatocellular carcinoma: Unique immunovascular characteristics.
Hepatology. 2025 Apr 1. doi: 10.1097/HEP.0000000000001339.
PubMed

MOL B, Werner E, Culver EL, van der Meer AJ, et al
Epidemiological and economical burden of cholestatic liver disease.
Hepatology. 2025 Apr 1. doi: 10.1097/HEP.0000000000001341.
PubMed Abstract available

March 2025

AHN JC, Ng WH, Yeo YH, Kim HS, et al
Comparative effectiveness of immunotherapy versus lenvatinib in advanced hepatocellular carcinoma: A real-world analysis using target trial emulation.
Hepatology. 2025 Mar 28. doi: 10.1097/HEP.0000000000001328.
PubMed Abstract available

GUO Y, Wang J, Zhang L, Shen S, et al
Erratum: Theranostical nanosystem-mediated identification of an oncogene and highly effective therapy in hepatocellular carcinoma.
Hepatology. 2025 Mar 27. doi: 10.1097/HEP.0000000000001240.
PubMed

KIM KE, Lee J, Shin HJ, Jeong EA, et al
Erratum: Lipocalin-2 activates hepatic stellate cells and promotes nonalcoholic steatohepatitis in high-fat diet-fed Ob/Ob mice.
Hepatology. 2025 Mar 27. doi: 10.1097/HEP.0000000000001287.
PubMed

LAI JC, Shui AM, Molinari M, Rahimi R, et al
The Liver Transplant Comorbidity Index (LTCI) : A composite index of ambulatory Pre-LT factors to identify patients at increased risk of Post-LT Mortality.
Hepatology. 2025 Mar 25. doi: 10.1097/HEP.0000000000001320.
PubMed Abstract available

MACIAS RIR, Roessler S, Verstegen MMA
Deciphering the spatial tumor microenvironment in intrahepatic cholangiocarcinoma.
Hepatology. 2025 Mar 24. doi: 10.1097/HEP.0000000000001322.
PubMed

SU R, Tao X, Yan L, Liu Y, et al
Early screening, diagnosis and recurrence monitoring of hepatocellular carcinoma in chronic hepatitis B patients based on serum N-glycomics analysis: A cohort study.
Hepatology. 2025 Mar 21. doi: 10.1097/HEP.0000000000001316.
PubMed Abstract available

TSENG TC, Hosaka T, Pan MH, Liu CJ, et al
Higher level of Hepatitis B Surface antigen associated with delayed development of hepatocellular carcinoma in immune-tolerant patients.
Hepatology. 2025 Mar 20. doi: 10.1097/HEP.0000000000001313.
PubMed Abstract available

WONG CC, Wong CM
CAD-Driven pathways in hepatocellular carcinoma metastasis.
Hepatology. 2025 Mar 19. doi: 10.1097/HEP.0000000000001315.
PubMed

CHEN S, Shen L, Fan W
Letter to the Editor: The divergences in the efficacy of adjuvant transarterial chemoembolization for hepatocellular carcinoma: In-depth analysis and enlightenments.
Hepatology. 2025 Mar 18. doi: 10.1097/HEP.0000000000001310.
PubMed

ZHANG T, Huang CJ, Chen HT, Huang YH, et al
HLA-DQB1*03:01 and risk of Hepatitis B virus-related hepatocellular carcinoma.
Hepatology. 2025 Mar 14. doi: 10.1097/HEP.0000000000001307.
PubMed Abstract available

ZHAO Q, Liu H, Yang Z, Han X, et al
Pre-B-Cell leukemia transcription factor 1 contributes to liver fibrosis by enabling IL-7 signaling in hepatic stellate cells.
Hepatology. 2025 Mar 13. doi: 10.1097/HEP.0000000000001302.
PubMed Abstract available

PAN J, Zhang M, Rao D, Ma J, et al
CAD manipulates tumor intrinsic DHO/UBE4B/NF-kappaB pathway and fuels macrophage cross-talk, promoting hepatocellular carcinoma metastasis.
Hepatology. 2025 Mar 12. doi: 10.1097/HEP.0000000000001304.
PubMed Abstract available

MONTAGNESE S, Duarte-Rojo A
Hepatic encephalopathy - We are no longer those who believe that reality is what we perceive.
Hepatology. 2025 Mar 12. doi: 10.1097/HEP.0000000000001308.
PubMed

LI PJ, Tabrizian P, Daher D, Gaviria F, et al
A prospective multicenter validation of RETREAT for post-transplantation hepatocellular carcinoma recurrence prediction.
Hepatology. 2025 Mar 11. doi: 10.1097/HEP.0000000000001297.
PubMed Abstract available

AHN JC, Noh YK, Hu M, Shen X, et al
AI-driven synthetic data generation for accelerating hepatology research: A study of the United Network for Organ Sharing (UNOS) database.
Hepatology. 2025 Mar 11. doi: 10.1097/HEP.0000000000001299.
PubMed Abstract available

WANG P, Zhong L
Letter to the Editor: Downstaging of hepatocellular carcinoma before liver transplantation: More details, more significance.
Hepatology. 2025 Mar 10. doi: 10.1097/HEP.0000000000001301.
PubMed

XU E, Mehta N
Reply: Downstaging of hepatocellular carcinoma before liver transplantation.
Hepatology. 2025 Mar 10. doi: 10.1097/HEP.0000000000001303.
PubMed

CULLARO G, Allegretti AS, Patidar KR, Jamil K, et al
The relationship between mean arterial pressure and terlipressin in hepatorenal syndrome-acute kidney injury reversal: a post hoc analysis.
Hepatology. 2025 Mar 7. doi: 10.1097/HEP.0000000000001295.
PubMed Abstract available

MOECKLI B, Wassmer CH, El Hajji S, Kumar R, et al
Determining safe washout period for immune checkpoint inhibitors prior to liver transplantation: An international retrospective cohort study.
Hepatology. 2025 Mar 5. doi: 10.1097/HEP.0000000000001289.
PubMed Abstract available

SUN Y, Li T, Ding L, Wang J, et al
Platelet-mediated circulating tumor cell evasion from natural killer cell killing through immune checkpoint CD155-TIGIT.
Hepatology. 2025;81:791-807.
PubMed Abstract available

NAKATSUKA T, Tateishi R, Sato M, Hashizume N, et al
Deep learning and digital pathology powers prediction of HCC development in steatotic liver disease.
Hepatology. 2025;81:976-989.
PubMed Abstract available

SASAKI K, Rooge S, Gunewardena S, Hintz JA, et al
Kupffer cell diversity maintains liver function in alcohol-associated liver disease.
Hepatology. 2025;81:870-887.
PubMed Abstract available

HAN S, Fan H, Zhong G, Ni L, et al
Nuclear KRT19 is a transcriptional corepressor promoting histone deacetylation and liver tumorigenesis.
Hepatology. 2025;81:808-822.
PubMed Abstract available

KIM D, Shah M, Kim JH, Kim J, et al
Integrative transcriptomic and genomic analyses unveil the IFI16 variants and expression as MASLD progression markers.
Hepatology. 2025;81:962-975.
PubMed Abstract available

LIU LZ, Zhang Z, Zheng BH, Shi Y, et al
Erratum: CCL15 recruits suppressive monocytes to facilitate immune escape and disease progression in hepatocellular carcinoma.
Hepatology. 2025;81:E113-E114.
PubMed

DHANASEKARAN R, Suzuki H, Lemaitre L, Kubota N, et al
Molecular and immune landscape of hepatocellular carcinoma to guide therapeutic decision-making.
Hepatology. 2025;81:1038-1057.
PubMed Abstract available

February 2025

TANIAI T, Shimada S, Akiyama Y, Hatano M, et al
Integrative transcriptome profiling elucidates molecular and immunovascular characteristics of macrotrabecular hepatocellular carcinoma.
Hepatology. 2025 Feb 26. doi: 10.1097/HEP.0000000000001284.
PubMed Abstract available

VOLKERT I, Grube J, Woitok MM, Mohamed MR, et al
Selective genetic inactivation of Caspase 8 in hepatocytes ameliorates progression of MASH following Jnk deficiency.
Hepatology. 2025 Feb 26. doi: 10.1097/HEP.0000000000001286.
PubMed Abstract available

LIAO W, Zhang Y, Wang J, Cui G, et al
beta-Catenin regulates distinct pathways from YAP and suppresses ONECUT1 to drive hepatoblastoma development in mice and humans.
Hepatology. 2025 Feb 25. doi: 10.1097/HEP.0000000000001280.
PubMed Abstract available

HONG L, Mei J, Sun X, Wu Y, et al
Spatial single-cell proteomics landscape decodes the tumor microenvironmental ecosystem of intrahepatic cholangiocarcinoma.
Hepatology. 2025 Feb 25. doi: 10.1097/HEP.0000000000001283.
PubMed Abstract available

CARDOSO FS
Letter to the Editor: Mean arterial pressure as a complex treatment target in patients with cirrhosis and acute kidney injury.
Hepatology. 2025 Feb 25. doi: 10.1097/HEP.0000000000001288.
PubMed

TADDEI TH, Brown DB, Yarchoan M, Mendiratta-Lala M, et al
Critical Update: AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma.
Hepatology. 2025 Feb 24. doi: 10.1097/HEP.0000000000001269.
PubMed

WANG ZC, Gao Q, Shi JY, Guo WJ, et al
Erratum: Protein tyrosine phosphatase receptor S acts as a metastatic suppressor in hepatocellular carcinoma by control of epithermal growth factor receptor-induced epithelial-mesenchymal transition.
Hepatology. 2025 Feb 18. doi: 10.1097/HEP.0000000000001176.
PubMed

WONG GL, Chan HL
Divergent trends in cirrhosis and liver cancer highlight the ongoing efforts required for hepatitis elimination.
Hepatology. 2025 Feb 18. doi: 10.1097/HEP.0000000000001273.
PubMed

CANCADO GGL, Deeb M, Gulamhusein AF
Liver transplantation for cholestatic liver diseases: Timing & disease recurrence.
Hepatology. 2025 Feb 17. doi: 10.1097/HEP.0000000000001268.
PubMed Abstract available

LEE EW, Saab S, Eghbalieh N, Ding PX, et al
Coil or Plug-Assisted Retrograde transvenous obliteration (CARTO/PARTO) for treating portal hypertensive variceal bleeding: A multi-center, real-world 10-year retrospective study.
Hepatology. 2025 Feb 5. doi: 10.1097/HEP.0000000000001255.
PubMed Abstract available

SOUZA M, Al-Sharif L, Antunes VLJ, Huang DQ, et al
Comparison of pharmacological therapies in metabolic dysfunction-associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis.
Hepatology. 2025 Feb 4. doi: 10.1097/HEP.0000000000001254.
PubMed Abstract available

BURTIS AEC, DeNicola DMC, Ferguson ME, Santos RG, et al
Ag-driven CD8 + T cell clonal expansion is a prominent feature of MASH in humans and mice.
Hepatology. 2025;81:591-608.
PubMed Abstract available

MOGA L, Paradis V, Ferreira-Silva J, Gudavalli K, et al
Performance of spleen stiffness measurement to rule out high-risk varices in patients with porto-sinusoidal vascular disorder.
Hepatology. 2025;81:546-559.
PubMed Abstract available

EL-SERAG HB, Jin Q, Tayob N, Salem E, et al
HES V2.0 outperforms GALAD for detection of HCC: A phase 3 biomarker study in the United States.
Hepatology. 2025;81:465-475.
PubMed Abstract available

FEIO-AZEVEDO R, Boesch M, Radenkovic S, van Melkebeke L, et al
Distinct immunometabolic signatures in circulating immune cells define disease outcome in acute-on-chronic liver failure.
Hepatology. 2025;81:509-522.
PubMed Abstract available

WONG YJ, Chen VL, Abdulhamid A, Tosetti G, et al
Comparing serial and current liver stiffness measurements to predict decompensation in compensated advanced chronic liver disease patients.
Hepatology. 2025;81:523-531.
PubMed Abstract available

DUARTE-ROJO A, Taouli B, Leung DH, Levine D, et al
Imaging-based noninvasive liver disease assessment for staging liver fibrosis in chronic liver disease: A systematic review supporting the AASLD Practice Guideline.
Hepatology. 2025;81:725-748.
PubMed Abstract available

MARINO L, Kim A, Ni B, Celi FS, et al
Thyroid hormone action and liver disease, a complex interplay.
Hepatology. 2025;81:651-669.
PubMed Abstract available

January 2025

ZHANG Z, Zhang Z, Zhang Y, Li Y, et al
Phosphoproteomics delineates hepatocellular carcinoma subtypes and pinpoints therapeutic targets.
Hepatology. 2025 Jan 31. doi: 10.1097/HEP.0000000000001250.
PubMed Abstract available

LIU Q, Li J, Chen H, Song J, et al
Letter to the Editor: Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment.
Hepatology. 2025 Jan 31. doi: 10.1097/HEP.0000000000001215.
PubMed

YOUNOSSI ZM, de Avila L, Racila A, Nader F, et al
Prevalence and predictors of cirrhosis and portal hypertension in the united states.
Hepatology. 2025 Jan 29. doi: 10.1097/HEP.0000000000001243.
PubMed Abstract available

CHENG K, Cai N, Yang X, Li D, et al
Short-term starvation boosts anti-PD-L1 therapy by reshaping tumor-associated macrophages in hepatocellular carcinoma.
Hepatology. 2025 Jan 29. doi: 10.1097/HEP.0000000000001244.
PubMed Abstract available

DESPLATS V, Haudebourg L, Verger N, Assaraf J, et al
Acute encephalopathy without hyperammonemia has a different presentation than overt hepatic encephalopathy and displays similarly severe prognosis.
Hepatology. 2025 Jan 29. doi: 10.1097/HEP.0000000000001252.
PubMed Abstract available

SEO DH, Sung PS
Reply: Intrahepatic immunoglobulin a complex induces polarization of cancer-associated fibroblasts to matrix phenotypes in the tumor microenvironment of hepatocellular carcinoma_reply.
Hepatology. 2025 Jan 28. doi: 10.1097/HEP.0000000000001253.
PubMed

LU Z, Wong CM
The impact of LRP4 mutations on hepatocellular carcinoma recurrence and immunotherapy response.
Hepatology. 2025 Jan 16. doi: 10.1097/HEP.0000000000001235.
PubMed

YANG DL, Ye L, Zeng FJ, Liu J, et al
Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermedi
Hepatology. 2025 Jan 15. doi: 10.1097/HEP.0000000000001229.
PubMed Abstract available

XU E, Tabrizian P, Gutierrez J, Hoteit M, et al
Downstaging of hepatocellular carcinoma before liver transplantation: Results from a national multi-center prospective cohort study.
Hepatology. 2025 Jan 14. doi: 10.1097/HEP.0000000000001231.
PubMed Abstract available

MA T, Bai X, Zhang Q, Chen W, et al
Adjuvant transarterial chemoembolization for hepatocellular carcinoma following curative resection: A randomized, open-label, phase 3 trial.
Hepatology. 2025 Jan 14. doi: 10.1097/HEP.0000000000001233.
PubMed Abstract available

LIU D, Chen L, Wang Z, Li Z, et al
Ubiquitination of TFEB increased intestinal permeability to aggravate metabolic dysfunction-associated steatohepatitis.
Hepatology. 2025 Jan 10. doi: 10.1097/HEP.0000000000001214.
PubMed Abstract available

OBRADOVIC F, Vitello DJ, Hasjim BJ, Obayemi J, et al
Comparing the cost of cirrhosis to other common chronic diseases: A longitudinal study in a large national insurance database.
Hepatology. 2025 Jan 6. doi: 10.1097/HEP.0000000000001206.
PubMed Abstract available

ROCCARINA D, Saltini D, Adotti V, Rosi M, et al
End-procedural adherence to recommended hemodynamic targets does not improve the outcome of elective tips in cirrhotic patients.
Hepatology. 2025 Jan 3. doi: 10.1097/HEP.0000000000001224.
PubMed Abstract available

KABELITZ MA, Hartl L, Schaub G, Tiede A, et al
Identification of optimal portal pressure decrease to control ascites while minimizing hepatic encephalopathy after TIPS: A multicenter study.
Hepatology. 2025 Jan 3. doi: 10.1097/HEP.0000000000001219.
PubMed Abstract available

RONCA V, Davies SP, Oo YH, Lleo A, et al
The immunological landscape of primary biliary cholangitis: Mechanisms and therapeutic prospects.
Hepatology. 2025 Jan 3. doi: 10.1097/HEP.0000000000001225.
PubMed Abstract available

KWAK M, Kim HS, Jiang ZG, Yeo YH, et al
MASLD/MetALD and mortality in individuals with any cardio-metabolic risk factor: A population-based study with 26.7 years of follow-up.
Hepatology. 2025;81:228-237.
PubMed Abstract available

HOBEIKA C, Ronot M, Guiu B, Ferraioli G, et al
Ultrasound-based steatosis grading system using 2D-attenuation imaging: An individual patient data meta-analysis with external validation.
Hepatology. 2025;81:212-227.
PubMed Abstract available

KE C, Xiao C, Li J, Wu X, et al
FMO2 ameliorates nonalcoholic fatty liver disease by suppressing ER-to-Golgi transport of SREBP1.
Hepatology. 2025;81:181-197.
PubMed Abstract available

Erratum: Expression and functional significance of Twist1 in hepatocellular carcinoma: Its role in vasculogenic mimicry.
Hepatology. 2025;81:E26-E27.
PubMed

WILECHANSKY RM
Putting mean arterial pressure on the map as an AKI biomarker in cirrhosis.
Hepatology. 2025;81:3-4.
PubMed

December 2024

CELSA C, Cabibbo G, Pinato DJ
Reply: Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment.
Hepatology. 2024 Dec 25. doi: 10.1097/HEP.0000000000001217.
PubMed

SUN R, Liu K, Pan S, Ye Y, et al
LRP4 mutations promote tumour progression and resistance to anti-PD-1 therapy in recurrent hepatocellular carcinoma.
Hepatology. 2024 Dec 24. doi: 10.1097/HEP.0000000000001212.
PubMed Abstract available

MA S, Chen J, Li J
Letter to the editor: Intrahepatic immunoglobulin A complex induces polarization of cancer-associated fibroblasts to matrix phenotypes in the tumor microenvironment of hepatocellular carcinoma.
Hepatology. 2024 Dec 23. doi: 10.1097/HEP.0000000000001197.
PubMed

TAO J, Wu Z, Liang Y, Wang J, et al
Lhx2 specifically expressed in hepatic stellate cells promotes liver regeneration and inhibits liver fibrosis.
Hepatology. 2024 Dec 18. doi: 10.1097/HEP.0000000000001201.
PubMed Abstract available

VUTIEN P, Barnard Giustini A, Kim NJ, Moon AM, et al
Validation and expansion of Baveno VII criteria for cACLD and CSPH based on liver stiffness and platelet count: Correlation with risk of hepatic decompensation and death.
Hepatology. 2024 Dec 17. doi: 10.1097/HEP.0000000000001183.
PubMed Abstract available

YANG Y, Ni Q, Li H, Sun J, et al
Genomic and the tumor microenvironment heterogeneity in multifocal hepatocellular carcinoma.
Hepatology. 2024 Dec 12. doi: 10.1097/HEP.0000000000001191.
PubMed Abstract available

CONDE DE LA ROSA L, Fabrega L, Torres S, Nunez S, et al
Stard1 promotes cholestatic liver injury and disease progression by sensitizing to bile acid hepatotoxicity.
Hepatology. 2024 Dec 9. doi: 10.1097/HEP.0000000000001184.
PubMed Abstract available

GONZALEZ-RECIO I, Goikoetxea-Usandizaga N, Rejano-Gordillo CM, Conter C, et al
Modulatory effects of CNNM4 on Protein-L-Isoaspartyl-O-Methyltransferase repair function during Alcohol-Induced hepatic damage.
Hepatology. 2024 Dec 6. doi: 10.1097/HEP.0000000000001156.
PubMed Abstract available

BROOKHART MA, Mayne TJ, Coombs C, Breskin A, et al
Hepatic real-world outcomes with obeticholic acid in primary biliary cholangitis (HEROES): A trial emulation study design.
Hepatology. 2024 Dec 2. doi: 10.1097/HEP.0000000000001174.
PubMed Abstract available

HUI RW, Chiu KW, Lee IC, Wang C, et al
Multimodal multiphasic pre-operative image-based deep-learning predicts hepatocellular carcinoma outcomes after curative surgery.
Hepatology. 2024 Dec 2. doi: 10.1097/HEP.0000000000001180.
PubMed Abstract available

SENGUPTA S, Gill V, Mellinger JL
Alcohol-associated liver disease and public health policies.
Hepatology. 2024;80:1323-1341.
PubMed Abstract available

HAQUE LY, Leggio L
Integrated and collaborative care across the spectrum of alcohol-associated liver disease and alcohol use disorder.
Hepatology. 2024;80:1408-1423.
PubMed Abstract available

MAREK GW, Malhi H
MetALD: Does it require a different therapeutic option?
Hepatology. 2024;80:1424-1440.
PubMed Abstract available

NARAYANAN P, Wu T, Shah VH, Curtis BL, et al
Insights into ALD and AUD diagnosis and prognosis: Exploring AI and multimodal data streams.
Hepatology. 2024;80:1480-1494.
PubMed Abstract available

RAYA TONETTI F, Eguileor A, Mrdjen M, Pathak V, et al
Gut-liver axis: Recent concepts in pathophysiology in alcohol-associated liver disease.
Hepatology. 2024;80:1342-1371.
PubMed Abstract available

ABERG F, Jiang ZG, Cortez-Pinto H, Mannisto V, et al
Alcohol-associated liver disease-Global epidemiology.
Hepatology. 2024;80:1307-1322.
PubMed Abstract available

FU Y, Maccioni L, Wang XW, Greten TF, et al
Alcohol-associated liver cancer.
Hepatology. 2024;80:1462-1479.
PubMed Abstract available

ISRAELSEN M, Rungratanawanich W, Thiele M, Liangpunsakul S, et al
Non-invasive tests for alcohol-associated liver disease.
Hepatology. 2024;80:1390-1407.
PubMed Abstract available

November 2024

VERCHER E, Covo-Vergara A, Conde E, Hernandez-Rueda M, et al
Human T cells engineered with an HLA-A2-restricted murine T-cell receptor targeting Glypican 3 effectively control human hepatocellular carcinoma in mice.
Hepatology. 2024 Nov 26. doi: 10.1097/HEP.0000000000001175.
PubMed Abstract available

HAN J, Shan D
Letter to the Editor: Refining the role of HAF in hepatocellular carcinoma.
Hepatology. 2024 Nov 21. doi: 10.1097/HEP.0000000000001171.
PubMed

SCHEINER B, Kang B, Balcar L, Radu IP, et al
Outcome and management of patients with hepatocellular carcinoma who achieved a complete response to immunotherapy-based systemic therapy.
Hepatology. 2024 Nov 21. doi: 10.1097/HEP.0000000000001163.
PubMed Abstract available

SUMMERS SA, Koh MY
Reply: Refining the role of HAF in hepatocellular carcinoma.
Hepatology. 2024 Nov 21. doi: 10.1097/HEP.0000000000001173.
PubMed

WONG YJ, Teng M, Sim A, Abraldes JG, et al
Reply: Quality indicators and the safety profile of endoscopic intervention in patients with bleeding esophageal varices.
Hepatology. 2024 Nov 12. doi: 10.1097/HEP.0000000000001155.
PubMed

LEVY C, Bowlus CL
Primary Biliary Cholangitis: personalizing second-line therapies.
Hepatology. 2024 Nov 12. doi: 10.1097/HEP.0000000000001166.
PubMed Abstract available

JOHN BV, Bastaich D, Dahman B
Reply: Association of hepatitis delta virus infection and hepatocellular carcinoma, hepatic decompensation, all-cause and liver-related death in a national cohort.
Hepatology. 2024 Nov 11. doi: 10.1097/HEP.0000000000001162.
PubMed

KRIGE JE, Jonas EG, Bernon MM
Letter to the editor: Quality indicators and the safety profile of endoscopic intervention in patients with bleeding esophageal varices.
Hepatology. 2024 Nov 11. doi: 10.1097/HEP.0000000000001153.
PubMed

HE Z, Wang C, Tian H
Letter to the editor : Association of hepatitis delta virus infection and hepatocellular carcinoma, hepatic decompensation, all-cause and liver-related death in a national cohort.
Hepatology. 2024 Nov 11. doi: 10.1097/HEP.0000000000001159.
PubMed

BRUNO BJ, Weavil JC, Ogle J, Chidambaram N, et al
Oral LPCN 1148 improves sarcopenia and hepatic encephalopathy in male patients with cirrhosis: A randomized, placebo-controlled phase 2 trial.
Hepatology. 2024 Nov 8. doi: 10.1097/HEP.0000000000001146.
PubMed Abstract available

LI S, Wu Z
Letter to the Editor: Enhancing automated speech analysis for hepatic encephalopathy detection.
Hepatology. 2024 Nov 7. doi: 10.1097/HEP.0000000000001150.
PubMed

LIAO TL, Chen DY, Hsieh SL, Yang YY, et al
Platelet-derived mitochondria regulate lipid metabolism in nonalcoholic steatohepatitis via extracellular vesicles.
Hepatology. 2024 Nov 7. doi: 10.1097/HEP.0000000000001149.
PubMed Abstract available

ALVARADO-TAPIAS E, Brujats A, Puente A, Ardevol A, et al
Hemodynamic effects of carvedilol plus simvastatin in cirrhosis with severe portal hypertension and suboptimal response to beta-blockers: A double-blind, placebo-controlled, randomized-trial.
Hepatology. 2024 Nov 7. doi: 10.1097/HEP.0000000000001148.
PubMed Abstract available

BLOOM PP, Lok AS
Reply: Enhancing automated speech analysis for hepatic encephalopathy detection.
Hepatology. 2024 Nov 7. doi: 10.1097/HEP.0000000000001151.
PubMed

CHARU V, Liang JW, Mannalithara A, Kwong A, et al
Benchmarking clinical risk prediction algorithms with ensemble machine learning for the noninvasive diagnosis of liver fibrosis in NAFLD.
Hepatology. 2024;80:1184-1195.
PubMed Abstract available

CHALASANI N, Vilar-Gomez E, Loomba R, Yates KP, et al
PNPLA3 rs738409, age, diabetes, sex, and advanced fibrosis jointly contribute to the risk of major adverse liver outcomes in metabolic dysfunction-associated steatotic liver disease.
Hepatology. 2024;80:1212-1226.
PubMed Abstract available

STONEBRAKER JR, Pace RG, Gallins PJ, Dang H, et al
Genetic variation in severe cystic fibrosis liver disease is associated with novel mechanisms for disease pathogenesis.
Hepatology. 2024;80:1012-1025.
PubMed Abstract available

GE J, Sun S, Owens J, Galvez V, et al
Development of a liver disease-specific large language model chat interface using retrieval-augmented generation.
Hepatology. 2024;80:1158-1168.
PubMed Abstract available

ZHANG L, Jiao K, Liu Y, Xu G, et al
UBXN9 inhibits the RNA exosome function to promote T cell control of liver tumorigenesis.
Hepatology. 2024;80:1041-1057.
PubMed Abstract available

GAO W, Zhang L, Li Z, Wu T, et al
Nuclear Acly protects the liver from ischemia-reperfusion injury.
Hepatology. 2024;80:1087-1103.
PubMed Abstract available

Erratum: NK-cell-elicited gasdermin-D-dependent hepatocyte pyroptosis induces neutrophil extracellular traps that facilitates HBV-related acute-on-chronic liver failure.
Hepatology. 2024;80:E92.
PubMed

Erratum: Basolateral CD147 induces hepatocyte polarity loss by E-cadherin ubiquitination and degradation in hepatocellular carcinoma progress.
Hepatology. 2024;80:E91.
PubMed

Erratum: Diagnosis, Evaluation, and Management of Ascites and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases.
Hepatology. 2024;80:E89.
PubMed

NARAYANAN P
PAR for the liver course: Preserving platelet function mitigates outcomes in cirrhosis.
Hepatology. 2024;80:991-992.
PubMed

October 2024

FAN G, Tao C, Li L, Xie T, et al
The co-location of MARCO+ tumor-associated macrophages and CTSE+ tumor cells determined the poor prognosis in intrahepatic cholangiocarcinoma.
Hepatology. 2024 Oct 29. doi: 10.1097/HEP.0000000000001138.
PubMed Abstract available

VONADA A, Grompe M
In vivo selection of hepatocytes.
Hepatology. 2024 Oct 29. doi: 10.1097/HEP.0000000000001143.
PubMed Abstract available

CIRIA R, Ivanics T, Aliseda D, Claasen M, et al
Liver transplantation for primary and secondary liver tumours. patient-level meta-analyses compared to unos conventional indications.
Hepatology. 2024 Oct 28. doi: 10.1097/HEP.0000000000001129.
PubMed Abstract available

KIM JW, Tung HC, Ke M, Xu P, et al
The de-sulfinylation enzyme sulfiredoxin-1 attenuates hepatic stellate cell activation and liver fibrosis by modulating the PTPN12-NLRP3 axis.
Hepatology. 2024 Oct 24. doi: 10.1097/HEP.0000000000001133.
PubMed Abstract available

ZHOU K, Wang Z, Guo W, Xie F, et al
Unraveling bidirectional evolution of unstable mitochondrial DNA mutations in hepatocellular carcinoma at single-cell resolution.
Hepatology. 2024 Oct 11. doi: 10.1097/HEP.0000000000001113.
PubMed Abstract available

KEZER CA, Berzigotti A, Fortune BE, Simonetto DA, et al
Drug treatments to prevent first decompensation in cirrhosis.
Hepatology. 2024 Oct 8. doi: 10.1097/HEP.0000000000001117.
PubMed Abstract available

FAR A, Bastani A, Lee A, Gologorskaya O, et al
Evaluating the positive predictive value of code-based identification of cirrhosis and its complications utilizing GPT-4.
Hepatology. 2024 Oct 8. doi: 10.1097/HEP.0000000000001115.
PubMed Abstract available

NAKAGAWA H
New ubiquitomic subtypes in hepatocellular carcinoma: Insights for future therapeutic approaches.
Hepatology. 2024 Oct 7. doi: 10.1097/HEP.0000000000001116.
PubMed

GIRI N, Niewisch MR, Rosenberg PS, Vittal A, et al
Reply: Accurate predictor for liver disease progression in patients with DC/TBD.
Hepatology. 2024;80:E61-E62.
PubMed

ZHAO J, Bi Y
Letter to the Editor: Accurate predictor for liver disease progression in patients with DC/TBD.
Hepatology. 2024;80:E60.
PubMed

EL-SHABRAWI MHF, Elamin A, Kamal NM
Letter to the Editor: MAFLD versus MASLD criteria debate- Certainly not for children!
Hepatology. 2024;80:E55-E56.
PubMed

LA VECCHIA C, Santucci C
Liver cancer in young adults: Validity of global data sets.
Hepatology. 2024;80:766-769.
PubMed

DANPANICHKUL P, Aboona MB, Sukphutanan B, Kongarin S, et al
Incidence of liver cancer in young adults according to the Global Burden of Disease database 2019.
Hepatology. 2024;80:828-843.
PubMed Abstract available

CHEUNG KS, Ng HY, Hui RWH, Lam LK, et al
Effects of empagliflozin on liver fat in patients with metabolic dysfunction-associated steatotic liver disease without diabetes mellitus: A randomized, double-blind, placebo-controlled trial.
Hepatology. 2024;80:916-927.
PubMed Abstract available

TANG S, Borlak J
Genomics of human NAFLD: Lack of data reproducibility and high interpatient variability in drug target expression as major causes of drug failures.
Hepatology. 2024;80:901-915.
PubMed Abstract available

SU GL, Zhang P, Belancourt PX, Youles B, et al
Incorporation of quantitative imaging data using artificial intelligence improves risk prediction in veterans with liver disease.
Hepatology. 2024;80:928-936.
PubMed Abstract available

PENRICE DD, Jalan-Sakrikar N, Jurk D, Passos JF, et al
Telomere dysfunction in chronic liver disease: The link from aging.
Hepatology. 2024;80:951-964.
PubMed

SAMPLE JW
Beyond monotherapy: Combining radiotherapy with sintilimab and bevacizumab for hepatocellular carcinoma with portal vein tumor thrombus.
Hepatology. 2024;80:757-758.
PubMed

September 2024

LIN XT, Luo YD, Mao C, Gong Y, et al
Integrated ubiquitomics characterization of hepatocellular carcinomas.
Hepatology. 2024 Sep 30. doi: 10.1097/HEP.0000000000001096.
PubMed Abstract available

KODAMA T
Geographical and molecular disparity of HBV integration: Implications for hepatocarcinogenesis and clinical outcomes in HCC.
Hepatology. 2024 Sep 30. doi: 10.1097/HEP.0000000000001111.
PubMed

NOUREDDIN M, Truong E, Mayo R, Martinez-Arranz I, et al
Letter to the Editor: Serum identification of At-Risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF).
Hepatology. 2024 Sep 26. doi: 10.1097/HEP.0000000000001061.
PubMed

AJOUAOU Y, Sadler KC
Uncovering epigenetic heterogeneity in hepatocellular carcinoma.
Hepatology. 2024 Sep 18. doi: 10.1097/HEP.0000000000001097.
PubMed

LYU X, Sze KM, Lee JM, Husain A, et al
Disparity landscapes of viral-induced structural variations in hepatocellular carcinoma: Mechanistic characterization and functional implications.
Hepatology. 2024 Sep 13. doi: 10.1097/HEP.0000000000001087.
PubMed Abstract available

BLOOM PP, Fisher CJ, Tedesco N, Kamdar N, et al
HEAR-MHE study: Automated speech analysis identifies minimal hepatic encephalopathy and may predict future overt hepatic encephalopathy.
Hepatology. 2024 Sep 12. doi: 10.1097/HEP.0000000000001086.
PubMed Abstract available

ACUNA-PILARTE K, Reichert EC, Song Green Y, Halberg LM, et al
HAF prevents hepatocyte apoptosis and progression to MASH and hepatocellular carcinoma through transcriptional regulation of the NF-kappaB pathway.
Hepatology. 2024 Sep 10. doi: 10.1097/HEP.0000000000001070.
PubMed Abstract available

JOHN BV, Bastaich D, Amoli MM, Wong RJ, et al
Association of hepatitis delta virus infection and hepatocellular carcinoma, hepatic decompensation, all-cause and liver-related death in a national cohort.
Hepatology. 2024 Sep 10. doi: 10.1097/HEP.0000000000001092.
PubMed Abstract available

YOUNOSSI ZM, Stepanova M, Racila A, Henry L, et al
Health-Related quality of life (HRQL) assessments in a 52-Week, Double-Blind, randomized, Placebo-Controlled phase 3 study of resmetirom (MGL-3196) in patients with metabolic dysfunction associated steatohepatitis (MASH) and fibrosis.
Hepatology. 2024 Sep 6. doi: 10.1097/HEP.0000000000001084.
PubMed Abstract available

WU Y, Li L, Li W, Li N, et al
Stretch-induced hepatic endothelial mechanocrine promotes hepatocyte proliferation.
Hepatology. 2024 Sep 6. doi: 10.1097/HEP.0000000000001082.
PubMed Abstract available

Hepatology Highlights.
Hepatology. 2024;80:501-502.
PubMed

VILLANI R, Serviddio G
Letter to the Editor: Multifactorial steatotic liver disease: A new entity to be included in new international classification of liver steatosis.
Hepatology. 2024;80:E40-E41.
PubMed

ALBORAIE M, Fouad Y, Eslam M
Letter to the Editor: MAFLD versus MASLD-Which is more appropriate from a global perspective?
Hepatology. 2024;80:E42-E43.
PubMed

CHUNG SW, Moon HS, Shin H, Han H, et al
Inhibition of sodium-glucose cotransporter-2 and liver-related complications in individuals with diabetes: a Mendelian randomization and population-based cohort study.
Hepatology. 2024;80:633-648.
PubMed Abstract available

TERBAH R, Testro AG, Hoermann R, Majumdar A, et al
Continuous home terlipressin infusion increases handgrip strength and reduces ascites-A prospective randomized crossover study.
Hepatology. 2024;80:605-620.
PubMed Abstract available

WATLING CZ, Wojt A, Florio AA, Butera G, et al
Fiber and whole grain intakes in relation to liver cancer risk: An analysis in 2 prospective cohorts and systematic review and meta-analysis of prospective studies.
Hepatology. 2024;80:552-565.
PubMed Abstract available

LIN P, Yan X, Jing S, Wu Y, et al
Single-cell and spatially resolved transcriptomics for liver biology.
Hepatology. 2024;80:698-720.
PubMed Abstract available

Hepatology Highlights.
Hepatology. 2024;80:501-502.
PubMed

August 2024

FACCIOLI LA, Sun Y, Animasahun O, Motomura T, et al
Human induced pluripotent stem cell based hepatic-modeling of lipid metabolism associated TM6SF2 E167K variant.
Hepatology. 2024 Aug 27. doi: 10.1097/HEP.0000000000001065.
PubMed Abstract available

LUCAS MR, Pilling LC, Atkins JL, Melzer D, et al
Incidence of liver complications with hemochromatosis associated HFE p.C282Y homozygosity: The role of central adiposity.
Hepatology. 2024 Aug 23. doi: 10.1097/HEP.0000000000001056.
PubMed Abstract available

VAN DER MEER AJ, Sonneveld MJ
Towards risk-based surveillance for hepatocellular carcinoma after HCV cure?
Hepatology. 2024 Aug 13. doi: 10.1097/HEP.0000000000001057.
PubMed

LIM HY, Heo J, Peguero JA, Ryoo BY, et al
Efficacy and safety of bintrafusp alfa in two phase 1 expansion cohorts with advanced hepatocellular carcinoma.
Hepatology. 2024 Aug 13. doi: 10.1097/HEP.0000000000001054.
PubMed Abstract available

BJORNSSON ES, Devarbhavi HC
Drug induced cholestatic liver diseases.
Hepatology. 2024 Aug 8. doi: 10.1097/HEP.0000000000001052.
PubMed Abstract available

SHANG Y, Akbari C, Dodd M, Zhang X, et al
Association between longitudinal biomarkers and major adverse liver outcomes in patients with non-cirrhotic metabolic dysfunction-associated steatotic liver disease.
Hepatology. 2024 Aug 7. doi: 10.1097/HEP.0000000000001045.
PubMed Abstract available

NAULT JC, Iavarone M
Management of patients with advanced hepatocellular carcinoma receiving atezolizumab/bevacizumab: Take care of cirrhosis!
Hepatology. 2024 Aug 5. doi: 10.1097/HEP.0000000000001047.
PubMed

Hepatology Highlights.
Hepatology. 2024;80:255-256.
PubMed

GARCIA-TSAO G, Kaplan DE
Reply: Endoscopy for potential variceal bleeding within 12 hours-Not so fast!
Hepatology. 2024;80:E36.
PubMed

RAMAN KP, Patch D
Tranexamic acid in variceal bleeding revisited.
Hepatology. 2024;80:257-259.
PubMed

JEPSEN P, West J, Kann AE, Kraglund F, et al
Risk of alcohol-associated liver disease in the offspring of parents with alcohol-associated liver disease: A nationwide cohort study.
Hepatology. 2024;80:418-427.
PubMed Abstract available

WANG Q, Bu Q, Pan B, Yin Y, et al
Letter to the Editor: Scavenger receptor a is a major homeostatic regulator that restrains drug-induced liver injury.
Hepatology. 2024;80:E24-E25.
PubMed

YANG D, Tian T, Li X, Zhang B, et al
ZNT1 and Zn 2+ control TLR4 and PD-L1 endocytosis in macrophages to improve chemotherapy efficacy against liver tumor.
Hepatology. 2024;80:312-329.
PubMed Abstract available

HLADY RA, Robertson KD
Epigenetic memory of environmental exposures as a mediator of liver disease.
Hepatology. 2024;80:451-464.
PubMed Abstract available

July 2024

LIM N, Devuni D, German M, Guy J, et al
The rise of multidisciplinary clinics in hepatology: A practical, how-to-guide, and review of the literature.
Hepatology. 2024 Jul 30. doi: 10.1097/HEP.0000000000001036.
PubMed Abstract available

WANG X, Liu Y, Zhang S, Zhang J, et al
Genomic and transcriptomic analyses of chemical hepatocarcinogenesis aggravated by oncoprotein loss.
Hepatology. 2024 Jul 30. doi: 10.1097/HEP.0000000000001037.
PubMed Abstract available

WANG M, Chiou SH, Ganger D, Ruck J, et al
Liver transplantation provides survival benefit at all levels of frailty: From the Multicenter Functional Assessment in Liver Transplantation Study.
Hepatology. 2024 Jul 24. doi: 10.1097/HEP.0000000000001030.
PubMed Abstract available

JEONG JM, Choi SE, Shim YR, Kim HH, et al
CX3CR1+ macrophages interact with hepatic stellate cells to promote hepatocellular carcinoma through CD8+ T cell suppression.
Hepatology. 2024 Jul 19. doi: 10.1097/HEP.0000000000001021.
PubMed Abstract available

CELSA C, Cabibbo G, Fulgenzi CAM, Battaglia S, et al
Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment.
Hepatology. 2024 Jul 19. doi: 10.1097/HEP.0000000000001026.
PubMed Abstract available

Diagnosis and Management of Hepatocellular Carcinoma.
Hepatology. 2024 Jul 17. doi: 10.1097/HEP.0000000000001010.
PubMed

ZHANG L, Xie P, Li M, Zhang X, et al
Hepatic GDP-fucose transporter SLC35C1 attenuates cholestatic liver injury and inflammation by inducing CEACAM1 N153 fucosylation.
Hepatology. 2024 Jul 10. doi: 10.1097/HEP.0000000000001003.
PubMed Abstract available

HUANG Y, Yu F, Ding Y, Zhang H, et al
Hepatic IL22RA1 deficiency promotes hepatic steatosis by modulating oxysterol in the liver.
Hepatology. 2024 Jul 10. doi: 10.1097/HEP.0000000000000998.
PubMed Abstract available

HOOVER JM
Letter to the Editor: Utilization of beta blockers in patients with portal hypertension and peripheral artery disease.
Hepatology. 2024 Jul 8. doi: 10.1097/HEP.0000000000001008.
PubMed

KENT D, Ng SS, Syanda AM, Khoshkenar P, et al
Reduction of Z alpha-1 antitrypsin polymers in human iPSC-hepatocytes and mice by LRRK2 inhibitors.
Hepatology. 2024 Jul 2. doi: 10.1097/HEP.0000000000000969.
PubMed Abstract available

Erratum: A prognostic strategy based on stage of cirrhosis and HVPG to improve risk stratification after variceal bleeding.
Hepatology. 2024;80:E23.
PubMed

Hepatology Highlights.
Hepatology. 2024;80:1-2.
PubMed

LAINE L, Barkun AN, Leontiadis GI
Letter to the Editor: Endoscopy for potential variceal bleeding within 12 hours-Not so fast!
Hepatology. 2024;80:E15-E16.
PubMed

KRAWCZYK M, Lammert F
Letter to the Editor: NAFLD vs. MASLD-There ain't no such thing as a free lunch.
Hepatology. 2024;80:E11-E12.
PubMed

RINELLA ME, Lazarus JV, Newsome PN
Reply: NAFLD vs. MASLD-There ain't no such thing as a free lunch.
Hepatology. 2024;80:E13-E14.
PubMed

MA J, Liangpunsakul S
Solving the puzzle of fibrosis resolution in alcohol-associated liver disease: An insight from KDM5 demethylases and LXR activation.
Hepatology. 2024;80:14-17.
PubMed

DAVENPORT M
Serum matrix metalloproteinase-7 (MMP-7): As good as it gets?
Hepatology. 2024;80:18-19.
PubMed

WOLTERS F, Oude Elferink RPJ, Beuers U
PPARalpha, PPARdelta, or both-that is the question!
Hepatology. 2024;80:8-10.
PubMed

KOSHIOL J, Krawczyk M
enHanCCing knowledge of genetic factors in primary liver tumor.
Hepatology. 2024;80:11-13.
PubMed

NEIL DAH, Smith ML, Minervini M, Demetris AJ, et al
Reply: Additional viewpoints from transplant surgeons on Banff consensus recommendations for the assessment of steatotic donor livers.
Hepatology. 2024;80:E6-E7.
PubMed

CAO H, Gu J
Letter to the Editor: Additional viewpoints from transplant surgeons on Banff consensus recommendations for the assessment of steatotic donor livers.
Hepatology. 2024;80:E4-E5.
PubMed

ABERG F, Asteljoki J, Mannisto V, Luukkonen PK, et al
Combined use of the CLivD score and FIB-4 for prediction of liver-related outcomes in the population.
Hepatology. 2024;80:163-172.
PubMed Abstract available

FLORIS A, Chandla S, Lim Y, Barbier-Torres L, et al
Sumoylation of methionine adenosyltransferase alpha 1 promotes mitochondrial dysfunction in alcohol-associated liver disease.
Hepatology. 2024;80:102-118.
PubMed Abstract available

LOPEZ-PASCUAL A
Navigating liver disease complexity: Innovations in in vitro modeling and precision medicine.
Hepatology. 2024;80:20-23.
PubMed

SCHONFELD M, O'Neil M, Weinman SA, Tikhanovich I, et al
Alcohol-induced epigenetic changes prevent fibrosis resolution after alcohol cessation in miceresolution.
Hepatology. 2024;80:119-135.
PubMed Abstract available

TONG Y, Wang F, Li S, Guo W, et al
Histone methyltransferase KMT5C drives liver cancer progression and directs therapeutic response to PARP inhibitors.
Hepatology. 2024;80:38-54.
PubMed Abstract available

SINGAL AK, Shah VH, Malhi H
Emerging targets for therapy in ALD: Lessons from NASH.
Hepatology. 2024;80:223-237.
PubMed Abstract available

Erratum: c-Jun mediates hepatitis C virus hepatocarcinogenesis through signal transducer and activator of transcription 3 and nitric oxide-dependent impairment of oxidative DNA repair.
Hepatology. 2024;80:E21.
PubMed

PREMKUMAR M, Karvellas CJ, Kulkarni AV, Bhujade H, et al
Role of Point-of-Care ultrasound (POCUS) in clinical hepatology.
Hepatology. 2024 Jul 1. doi: 10.1097/HEP.0000000000000990.
PubMed Abstract available

June 2024

GAO D, Ping Yam JW
Reversal of lipid metabolism as a therapeutic approach for hepatocellular carcinoma.
Hepatology. 2024 Jun 27. doi: 10.1097/HEP.0000000000001000.
PubMed

PREMKUMAR M, Kulkarni A, Izzy M
'Regarding Evaluation of terlipressin-related patient outcomes in hepatorenal syndrome-acute kidney injury using point-of-care echocardiography'.
Hepatology. 2024 Jun 26. doi: 10.1097/HEP.0000000000000988.
PubMed

LUO X, Yu J
Regarding terlipressin-related patient outcomes in hepatorenal syndrome-acute kidney injury.
Hepatology. 2024 Jun 25. doi: 10.1097/HEP.0000000000000984.
PubMed

RATZIU V, Yilmaz Y, Lazas D, Friedman SL, et al
Aramchol improves hepatic fibrosis in MASH: Results of multimodality assessment using both conventional and digital pathology.
Hepatology. 2024 Jun 25. doi: 10.1097/HEP.0000000000000980.
PubMed Abstract available

KANG K, Wu Y
Letter to the Editor: Regarding the use of decision curve analysis in predicting long-term complications of liver cirrhosis.
Hepatology. 2024 Jun 21. doi: 10.1097/HEP.0000000000000945.
PubMed

LI J, Ma X, Xuan Q, Li Q, et al
Modulation of monocyte activity by hepatocellular MicroRNA delivery via hepatitis B virus surface antigen particles: Implications for pathobiology of chronic hepatitis B.
Hepatology. 2024 Jun 20. doi: 10.1097/HEP.0000000000000972.
PubMed Abstract available

YANG M, Song X, Zhang F, Li M, et al
Spatial proteomic landscape of primary and relapsed hepatocellular carcinoma reveals immune escape characteristics in early relapse.
Hepatology. 2024 Jun 20. doi: 10.1097/HEP.0000000000000979.
PubMed Abstract available

BERENGUER J, Bellon JM, Banares R, Gonzalez-Garcia J, et al
Reply: Clinical outcomes and prognostic factors after HCV clearance with DAA in HIV/HCV-coinfected patients with advanced fibrosis/cirrhosis.
Hepatology. 2024 Jun 20. doi: 10.1097/HEP.0000000000000977.
PubMed

LIU Q, Zhang X, Qi J, Tian X, et al
Comprehensive profiling of lipid metabolic reprogramming expands precision medicine for hepatocellular carcinoma.
Hepatology. 2024 Jun 19. doi: 10.1097/HEP.0000000000000962.
PubMed Abstract available

SIMONETTO DA, Winder GS, Connor AA, Terrault NA, et al
Liver transplantation for Alcohol-associated liver disease.
Hepatology. 2024 Jun 18. doi: 10.1097/HEP.0000000000000978.
PubMed Abstract available

Process Measures to Improve Outcomes During Peri-Procedure Management of Coagulopathy in Cirrhosis.
Hepatology. 2024 Jun 17. doi: 10.1097/HEP.0000000000000964.
PubMed

HUANG L, Zou L
Letter to the Editor: Clinical outcomes and prognostic factors after HCV clearance with DAA in HIV/HCV-coinfected patients with advanced fibrosis/cirrhosis.
Hepatology. 2024 Jun 17. doi: 10.1097/HEP.0000000000000974.
PubMed

Erratum: Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3.
Hepatology. 2024;79:E171-E172.
PubMed

Hepatology Highlights.
Hepatology. 2024;79:1239-1240.
PubMed

LI Z, Zhang Y, Li Y, Lan J, et al
Letter to the Editor: Statins as potential confounding factors to investigate the association between the use of GLP-1 receptor agonists and risk of HCC.
Hepatology. 2024;79:E169-E170.
PubMed

LOMBARDI R, Dalbeni A, Mantovani A, Ravaioli F, et al
Reply: AGILE 3+ score, enhancing the diagnostic accuracy of advanced fibrosis in patients with nonalcoholic fatty liver disease.
Hepatology. 2024;79:E155-E156.
PubMed

CALZADILLA-BERTOT L, Jeffrey AW, Jeffrey GP
Letter to the Editor: AGILE 3+ score, enhancing the diagnostic accuracy of advanced fibrosis in patients with nonalcoholic fatty liver disease.
Hepatology. 2024;79:E153-E154.
PubMed

YEH JG, Newsome PN
Association of glucagon-like peptide-1 receptor agonists with serious liver events among patients with type 2 diabetes: A Scandinavian cohort study.
Hepatology. 2024;79:1255-1257.
PubMed

HANSEN BE, Vandriel SM, Vig P, Garner W, et al
Event-free survival of maralixibat-treated patients with Alagille syndrome compared to a real-world cohort from GALA.
Hepatology. 2024;79:1279-1292.
PubMed Abstract available

ABDELMALEK MF, Rinella ME
Steatotic liver disease, a useful construct in primary care that doesn't upset the apple cart.
Hepatology. 2024;79:1252-1254.
PubMed

ENGSTROM A, Wintzell V, Melbye M, Svanstrom H, et al
Association of glucagon-like peptide-1 receptor agonists with serious liver events among patients with type 2 diabetes: A Scandinavian cohort study.
Hepatology. 2024;79:1401-1411.
PubMed Abstract available

ZHAO G, Ma Q, Yang H, Jiang H, et al
Base editing of the mutated TERT promoter inhibits liver tumor growth.
Hepatology. 2024;79:1310-1323.
PubMed Abstract available

SCHMIDT KA, Simonetto DA
The telomere tango: Liver disease in the genomic spotlight.
Hepatology. 2024;79:1249-1251.
PubMed

SIDALI S, Borie R, Sicre de Fontbrune F, El Husseini K, et al
Liver disease in germline mutations of telomere-related genes: Prevalence, clinical, radiological, pathological features, outcome, and risk factors.
Hepatology. 2024;79:1365-1380.
PubMed Abstract available

UMBAUGH DS, Nguyen NT, Curry SC, Rule JA, et al
The chemokine CXCL14 is a novel early prognostic biomarker for poor outcome in acetaminophen-induced acute liver failure.
Hepatology. 2024;79:1352-1364.
PubMed Abstract available

WANG A, Blackford AL, Behling C, Wilson LA, et al
Development of Fibro-PeN, a clinical prediction model for moderate-to-severe fibrosis in children with nonalcoholic fatty liver disease.
Hepatology. 2024;79:1381-1392.
PubMed Abstract available

JIN Y, Shou Y, Lei Q, Du C, et al
An entropy weight method to integrate big omics and mechanistically evaluate DILI.
Hepatology. 2024;79:1264-1278.
PubMed Abstract available

AFONSO MB, Marques V, van Mil SWC, Rodrigues CMP, et al
Human liver organoids: From generation to applications.
Hepatology. 2024;79:1432-1451.
PubMed Abstract available

May 2024

MANTOVANI S, Mondelli MU
Platelets harness innate immunity to promote dissemination of hepatocellular carcinoma.
Hepatology. 2024 May 29. doi: 10.1097/HEP.0000000000000946.
PubMed

GUO C, Liu Z, Zhang T
Reply: Regarding the use of decision curve analysis in predicting long-term complications of liver cirrhosis.
Hepatology. 2024 May 29. doi: 10.1097/HEP.0000000000000947.
PubMed

MUSSO G, Pinach S, Mariano F, Saba F, et al
Effect of phospholipid curcumin Meriva(R) on liver histology and kidney disease in nonalcoholic steatohepatitis a randomized, double-blind, placebo-controlled trial.
Hepatology. 2024 May 28. doi: 10.1097/HEP.0000000000000937.
PubMed Abstract available

LI B, Yang Y, Shi J, Li Y, et al
Letter to the Editor: Molecular classification based on multi-omics facilitates prognostic stratification and personalized treatment in hepatocellular carcinoma.
Hepatology. 2024 May 28. doi: 10.1097/HEP.0000000000000944.
PubMed

MOORE MP, Wang X, Kennelly JP, Shi H, et al
Low MBOAT7 expression, a genetic risk for MASH, promotes a pro-fibrotic pathway involving hepatocyte TAZ upregulation.
Hepatology. 2024 May 22. doi: 10.1097/HEP.0000000000000933.
PubMed Abstract available

KANWAL F, Neuschwander-Tetri BA, Loomba R, Rinella ME, et al
Metabolic dysfunction-associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease.
Hepatology. 2024;79:1212-1219.
PubMed Abstract available

NABI O, Lapidus N, Boursier J, de Ledinghen V, et al
Reply: Concerns regarding the use of Fatty Liver Index in studies of lean NAFLD.
Hepatology. 2024;79:E130-E131.
PubMed

ZAHRAWI FM, Mehal WZ
Letter to the Editor: Concerns regarding the use of fatty liver index in studies of lean NAFLD.
Hepatology. 2024;79:E129.
PubMed

STOCKDALE AJ, Degasperi E
HDV RNA and liver disease progression: What do we know?
Hepatology. 2024;79:983-985.
PubMed

DESERT R, Foucher F, Guillout M, Nieto N, et al
Reply: Intratumor fibrotic HCC, a subtype matching the Hoshida S1 subclass?
Hepatology. 2024;79:E141-E143.
PubMed

WANG TC, Xiao YD, Zhou P
Letter to the Editor: Intratumor fibrotic HCC, a subtype matching the Hoshida S1 subclass?
Hepatology. 2024;79:E140.
PubMed

LIU H, Li H, Wang DX, Li T, et al
Letter to the Editor: Diagnostic accuracy of AGILE 3+ score for advanced fibrosis in patients with NAFLD: A systematic review and meta-analysis.
Hepatology. 2024;79:E144-E145.
PubMed

DALBENI A, Mantovani A, Lombardi R, Ravaioli F, et al
Reply: Diagnostic accuracy of AGILE3+ score for advanced fibrosis in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis.
Hepatology. 2024;79:E146-E147.
PubMed

KIRK FT, Munk DE, Swenson ES, Quicquaro AM, et al
Effects of trientine and penicillamine on intestinal copper uptake: A mechanistic 64 Cu PET/CT study in healthy humans.
Hepatology. 2024;79:1065-1074.
PubMed Abstract available

SQUIRES JE, Horslen SP
Incorporation of genetic testing into the diagnostic algorithms of PALF: The time is now.
Hepatology. 2024;79:970-972.
PubMed

DALBENI A, Lombardi R, Henrique M, Zoncape M, et al
Diagnostic accuracy of AGILE 3+ score for advanced fibrosis in patients with NAFLD: A systematic review and meta-analysis.
Hepatology. 2024;79:1107-1116.
PubMed Abstract available

LENZ D, Schlieben LD, Shimura M, Bianzano A, et al
Genetic landscape of pediatric acute liver failure of indeterminate origin.
Hepatology. 2024;79:1075-1087.
PubMed Abstract available

AJMERA V, Tesfai K, Sandoval E, Lopez S, et al
Validation of AGA clinical care pathway and AASLD practice guidance for nonalcoholic fatty liver disease in a prospective cohort of patients with type 2 diabetes.
Hepatology. 2024;79:1098-1106.
PubMed Abstract available

TONIUTTO P, Shalaby S, Mameli L, Morisco F, et al
Role of sex in liver tumor occurrence and clinical outcomes: A comprehensive review.
Hepatology. 2024;79:1141-1157.
PubMed Abstract available

SANTOS AA, Delgado TC, Marques V, Ramirez-Moncayo C, et al
Spatial metabolomics and its application in the liver.
Hepatology. 2024;79:1158-1179.
PubMed Abstract available

Erratum: Overexpressed-eIF3I interacted and activated oncogenic Akt1 is a theranostic target in human hepatocellular carcinoma.
Hepatology. 2024;79:E150-E151.
PubMed

April 2024

KUMAR M, Venishetty S
Reply: Tranexamic acid in upper gastrointestinal bleed in patients with cirrhosis - A randomized controlled trial.
Hepatology. 2024 Apr 30. doi: 10.1097/HEP.0000000000000916.
PubMed

ELKRIEF L, Denecheau-Girard C, Magaz M, Praktiknjo M, et al
Abdominal surgery in patients with chronic noncirrhotic extra hepatic portal vein obstruction: A multicenter retrospective study.
Hepatology. 2024 Apr 29. doi: 10.1097/HEP.0000000000000901.
PubMed Abstract available

LI X, Zhang Y, Li S, Shi J, et al
Macrophage hitchhiking for systematic suppression in postablative multifocal hepatocellular carcinoma.
Hepatology. 2024 Apr 29. doi: 10.1097/HEP.0000000000000903.
PubMed Abstract available

CHOPRA SY, Rawat VL, Ingle MA, Lad SG, et al
Letter to Editor: Tranexamic acid in upper gastrointestinal bleed in patients with cirrhosis - a randomized controlled trial.
Hepatology. 2024 Apr 29. doi: 10.1097/HEP.0000000000000915.
PubMed

OCHOA-ALLEMANT P, Serper M, Wang RX, Tang H, et al
Waitlisting and liver transplantation for MetALD in the United States: An analysis of the UNOS national registry.
Hepatology. 2024 Apr 29. doi: 10.1097/HEP.0000000000000914.
PubMed Abstract available

HITOMI Y, Ueno K, Aiba Y, Nishida N, et al
A genome-wide association study identified PTPN2 as a population-specific susceptibility gene locus for primary biliary cholangitis.
Hepatology. 2024 Apr 23. doi: 10.1097/HEP.0000000000000894.
PubMed Abstract available

LEE YT, Tseng HR, Yang JD
Clonal hematopoiesis of indeterminate potential and risk of hepatocellular carcinoma: New kids on the block.
Hepatology. 2024 Apr 19. doi: 10.1097/HEP.0000000000000898.
PubMed

GUO C, Liu Z, Fan H, Wang H, et al
Machine learning-based plasma metabolomic profiles for predicting long-term complications of cirrhosis.
Hepatology. 2024 Apr 17. doi: 10.1097/HEP.0000000000000879.
PubMed Abstract available

HAZARI Y, Chevet E, Bailly-Maitre B, Hetz C, et al
ER stress signaling at the interphase between MASH and hepatocellular carcinoma.
Hepatology. 2024 Apr 16. doi: 10.1097/HEP.0000000000000893.
PubMed Abstract available

PRZYBYSZEWSKI EM, Bhan I, Yarze JC
Letter to the Editor: On the use of non-selective beta blockers in cirrhosis.
Hepatology. 2024 Apr 16. doi: 10.1097/HEP.0000000000000888.
PubMed

GARCIA-TSAO G, Kaplan DE
Reply: On the use of non-selective beta blockers in cirrhosis.
Hepatology. 2024 Apr 16. doi: 10.1097/HEP.0000000000000889.
PubMed

VOLK ML
Innovations in Healthcare Delivery for Patients with Cirrhosis.
Hepatology. 2024 Apr 16. doi: 10.1097/HEP.0000000000000892.
PubMed

MOGHE A, McGuire BM, Levy C
Acute hepatic porphyrias - a guide for Hepatologists.
Hepatology. 2024 Apr 12. doi: 10.1097/HEP.0000000000000880.
PubMed Abstract available

SUN C, Zhou C, Daneshvar K, Ben Saad A, et al
Conserved long noncoding RNA TILAM promotes liver fibrosis through interaction with PML in hepatic stellate cells.
Hepatology. 2024 Apr 2. doi: 10.1097/HEP.0000000000000822.
PubMed Abstract available

LI J, Allen AM, Yin M
Reply: Comparing quantitative MRI technologies in steatotic liver disease.
Hepatology. 2024;79:E121-E122.
PubMed

ALKHOURI N, Harisinghani M
Letter to the Editor: Comparing quantitative MRI technologies in steatotic liver disease.
Hepatology. 2024;79:E119-E120.
PubMed

FRANSES JW, Duda DG
Scirrhous HCC: Another 'omic thread in the HCC tapestry.
Hepatology. 2024;79:747-748.
PubMed

VOLKERT I, Fromme M, Schneider C, Candels L, et al
Impact of PNPLA3 I148M on alpha-1 antitrypsin deficiency-dependent liver disease progression.
Hepatology. 2024;79:898-911.
PubMed Abstract available

LADD AD, Duarte S, Sahin I, Zarrinpar A, et al
Mechanisms of drug resistance in HCC.
Hepatology. 2024;79:926-940.
PubMed Abstract available

Erratum: Identification and characterization of a hepatic IL-13-producing ILC3-like population potentially involved in liver fibrosis.
Hepatology. 2024;79:E128.
PubMed

Erratum: HCC EV ECG score: An extracellular vesicle-based protein assay for detection of early-stage hepatocellular carcinoma.
Hepatology. 2024;79:E127.
PubMed

April 2024 Hepatology Highlights.
Hepatology. 2024;79:745-746.
PubMed

TAFALENG EN, Li J, Wang Y, Hidvegi T, et al
Variants in autophagy genes MTMR12 and FAM134A are putative modifiers of the hepatic phenotype in alpha1-antitrypsin deficiency.
Hepatology. 2024 Apr 1. doi: 10.1097/HEP.0000000000000865.
PubMed Abstract available

TAPPER EB, Warner MA, Shah RP, Emamaullee J, et al
Management of coagulopathy among patients with cirrhosis undergoing upper endoscopy and paracentesis: Persistent gaps and areas of consensus in a multispecialty Delphi.
Hepatology. 2024 Apr 1. doi: 10.1097/HEP.0000000000000856.
PubMed Abstract available

March 2024

Erratum: AASLD Practice Guidance on Acute-on-chronic liver failure and the management of critically ill patients with cirrhosis.
Hepatology. 2024 Mar 29. doi: 10.1097/HEP.0000000000000857.
PubMed

DENG T, Chen G
Single-cell based molecular classification in systematic treatment of hepatocellular carcinoma: From in silico to bedside.
Hepatology. 2024 Mar 28. doi: 10.1097/HEP.0000000000000874.
PubMed

CRUZ C, Prado CM, Gillis C, Martindale R, et al
Nutritional aspects of prehabilitation in adults with cirrhosis awaiting liver transplant.
Hepatology. 2024 Mar 28. doi: 10.1097/HEP.0000000000000818.
PubMed Abstract available

FENG X, Feng B, Zhou J, Yang J, et al
Mesenchymal stem cells alleviate mouse liver fibrosis by inhibiting pathogenic function of intrahepatic B cells.
Hepatology. 2024 Mar 28. doi: 10.1097/HEP.0000000000000831.
PubMed Abstract available

GOLDBERG DT, Yaskolka Meir A, Tsaban G, Rinott E, et al
Novel proteomic signatures may indicate MRI-assessed intrahepatic fat state and changes; the DIRECT PLUS clinical trial.
Hepatology. 2024 Mar 27. doi: 10.1097/HEP.0000000000000867.
PubMed Abstract available

ZHAO Q, Chen DP, Chen HD, Wang YZ, et al
NK-cell-elicited gasdermin-D-dependent hepatocyte pyroptosis induces neutrophil extracellular traps that facilitates HBV-related acute-on-chronic liver failure.
Hepatology. 2024 Mar 27. doi: 10.1097/HEP.0000000000000868.
PubMed Abstract available

CHEN Y, Deng X, Li Y, Han Y, et al
Comprehensive molecular classification predicted microenvironment profiles and therapy response for hepatocellular carcinoma.
Hepatology. 2024 Mar 27. doi: 10.1097/HEP.0000000000000869.
PubMed Abstract available

CULLARO G, Allegretti AS, Fenton C, Ge J, et al
The association between mean arterial pressure and acute kidney injury reversal among decompensated cirrhosis patients.
Hepatology. 2024 Mar 27. doi: 10.1097/HEP.0000000000000858.
PubMed Abstract available

WIGG AJ, Narayana S, Woodman RJ, Adams LA, et al
A randomized multicenter trial of a chronic disease management intervention for decompensated cirrhosis. The Australian Liver Failure (ALFIE) trial.
Hepatology. 2024 Mar 27. doi: 10.1097/HEP.0000000000000862.
PubMed Abstract available

MEROUEH C, Warasnhe K, Tizhoosh HR, Shah VH, et al
Digital pathology and spatial omics in steatohepatitis: Clinical applications and discovery potentials.
Hepatology. 2024 Mar 22. doi: 10.1097/HEP.0000000000000866.
PubMed Abstract available

JONES DE, Beuers U, Bonder A, Carbone M, et al
Primary biliary cholangitis drug evaluation and regulatory approval: Where do we go from here?
Hepatology. 2024 Mar 22. doi: 10.1097/HEP.0000000000000864.
PubMed Abstract available

STERLING RK, Asrani SK, Levine D, Duarte-Rojo A, et al
AASLD Practice Guideline on non-invasive liver disease assessments of portal hypertension.
Hepatology. 2024 Mar 15. doi: 10.1097/HEP.0000000000000844.
PubMed

STERLING RK, Patel K, Duarte-Rojo A, Asrani SK, et al
AASLD Practice Guideline on blood-based non-invasive liver disease assessments of hepatic fibrosis and steatosis.
Hepatology. 2024 Mar 15. doi: 10.1097/HEP.0000000000000845.
PubMed

STERLING RK, Duarte-Rojo A, Patel K, Asrani SK, et al
AASLD Practice Guideline on imaging-based non-invasive liver disease assessments of hepatic fibrosis and steatosis.
Hepatology. 2024 Mar 15. doi: 10.1097/HEP.0000000000000843.
PubMed

ROCKEY DC, Alsawas M, Rojo-Duarte A, Patel K, et al
Non-invasive liver disease assessment to identify portal hypertension: A systematic review supporting the AASLD Practice Guideline.
Hepatology. 2024 Mar 15. doi: 10.1097/HEP.0000000000000841.
PubMed Abstract available

DIETZ-FRICKE C, Degasperi E, Jachs M, Maasoumy B, et al
Safety and efficacy of off-label bulevirtide monotherapy in HDV patients with decompensated Child-B cirrhosis - a real world case series.
Hepatology. 2024 Mar 13. doi: 10.1097/HEP.0000000000000847.
PubMed Abstract available

MARCHETTI A, Pelusi S, Marella A, Malvestiti F, et al
Impact of clonal hematopoiesis of indeterminate potential on hepatocellular carcinoma in individuals with steatotic liver disease.
Hepatology. 2024 Mar 11. doi: 10.1097/HEP.0000000000000839.
PubMed Abstract available

BU W, Sun X, Xue X, Geng S, et al
Early onset of pathological polyploidization and cellular senescence in hepatocytes lacking RAD51 creates a pro-fibrotic and pro-tumorigenic inflammatory microenvironment.
Hepatology. 2024 Mar 11. doi: 10.1097/HEP.0000000000000821.
PubMed Abstract available

MUNOZ AE, Rodger EG
Letter to the Editor: Emerging role of statin therapy in the prevention and management of cirrhosis, portal hypertension, and HCC.
Hepatology. 2024 Mar 11. doi: 10.1097/HEP.0000000000000846.
PubMed

SHARPTON S, Loomba R
Response to Letter to the Editor: emerging role of statin therapy in the prevention and management of cirrhosis, portal hypertension, and HCC.
Hepatology. 2024 Mar 11. doi: 10.1097/HEP.0000000000000848.
PubMed

GUO Q, Wang J, Wang G, Wang X, et al
Letter to the Editor: Is right heart assessment vital for evaluating Terlipressin-related outcomes in Hepatorenal Syndrome-AKI?
Hepatology. 2024 Mar 8. doi: 10.1097/HEP.0000000000000832.
PubMed

CHAPMAN B, Wong D, Sinclair M, Hey P, et al
Reversing malnutrition and low muscle strength with targeted enteral feeding in patients awaiting liver transplant: A randomized controlled trial.
Hepatology. 2024 Mar 8. doi: 10.1097/HEP.0000000000000840.
PubMed Abstract available

BERENGUER J, Aldamiz-Echevarria T, Hontanon V, Fanciulli C, et al
Clinical outcomes and prognostic factors after HCV clearance with DAA in HIV/HCV coinfected patients with advanced Fibrosis/Cirrhosis.
Hepatology. 2024 Mar 7. doi: 10.1097/HEP.0000000000000838.
PubMed Abstract available

SEMMLER G, Hartl L, Mendoza YP, Simbrunner B, et al
Simple blood tests to diagnose compensated advanced chronic liver disease and stratify risk of clinically significant portal hypertension.
Hepatology. 2024 Mar 6. doi: 10.1097/HEP.0000000000000829.
PubMed Abstract available

AMPUERO J, Lucena A, Berenguer M, Hernandez-Guerra M, et al
Predictive factors for decompensating events in cirrhotic patients with primary biliary cholangitis under different lines of therapy.
Hepatology. 2024 Mar 6. doi: 10.1097/HEP.0000000000000826.
PubMed Abstract available

LAL BB, Alam S, Sibal A, Kumar K, et al
Genotype correlates with clinical course and outcome of children with tight junction protein 2 (TJP2) deficiency-related cholestasis.
Hepatology. 2024 Mar 6. doi: 10.1097/HEP.0000000000000828.
PubMed Abstract available

ROY A, Kajal K, Izzy M, Sihag BK, et al
Reply: Is right heart assessment vital for evaluating terlipressin-related outcomes in Hepatorenal Syndrome-AKI ?
Hepatology. 2024 Mar 5. doi: 10.1097/HEP.0000000000000833.
PubMed

KUMAR M, Venishetty S, Jindal A, Bihari C, et al
Tranexamic acid in upper gastrointestinal bleed in patients with cirrhosis - a randomized controlled trial.
Hepatology. 2024 Mar 5. doi: 10.1097/HEP.0000000000000817.
PubMed Abstract available

Erratum: An integrated analysis of fecal microbiome and metabolomic features distinguish non-cirrhotic NASH from healthy control populations.
Hepatology. 2024;79:E105.
PubMed

HOOFNAGLE JH, Doo E
Letter to the Editor: A multi-society Delphi consensus statement on new fatty liver disease nomenclature.
Hepatology. 2024;79:E91-E92.
PubMed

LAZARUS JV, Newsome PN, Francque SM, Kanwal F, et al
Reply: A multi-society Delphi consensus statement on new fatty liver disease nomenclature.
Hepatology. 2024;79:E93-E94.
PubMed

BARMAN-AKSOZEN J, Minder AE, Schuppan D, Stolzel U, et al
Letter to the Editor: Contrasting effect of iron supplementation in protoporphyria.
Hepatology. 2024;79:E87-E88.
PubMed

LEVY C, Dickey AK, Anderson KE, Keel SB, et al
Reply: Contrasting effect of iron supplementation in protoporphyria.
Hepatology. 2024;79:E89-E90.
PubMed

NICOARA-FARCAU O, Han G, Rudler M, Angrisani D, et al
Pre-emptive TIPS in high-risk acute variceal bleeding. An updated and revised individual patient data meta-analysis.
Hepatology. 2024;79:624-635.
PubMed Abstract available

WANG F, Chen L, Kong D, Zhang X, et al
Canonical Wnt signaling promotes HSC glycolysis and liver fibrosis through an LDH-A/HIF-1alpha transcriptional complex.
Hepatology. 2024;79:606-623.
PubMed Abstract available

LEE BP, Dodge JL, Terrault NA
National prevalence estimates for steatotic liver disease and subclassifications using consensus nomenclature.
Hepatology. 2024;79:666-673.
PubMed Abstract available

BARTEN TRM, Atsma F, van der Meer AJ, Gansevoort R, et al
Higher need for polycystic liver disease therapy in female patients: Sex-specific association between liver volume and need for therapy.
Hepatology. 2024;79:551-559.
PubMed Abstract available

LEDENKO M, Antwi SO, Patel T
Geospatial analysis of cyanobacterial exposure and liver cancer in the contiguous United States.
Hepatology. 2024;79:575-588.
PubMed Abstract available

LEVY C, Dickey AK, Wang B, Thapar M, et al
Evidence-based consensus guidelines for the diagnosis and management of protoporphyria-related liver dysfunction in erythropoietic protoporphyria and X-linked protoporphyria.
Hepatology. 2024;79:731-743.
PubMed

Hepatology Highlights.
Hepatology. 2024;79:525-526.
PubMed

February 2024

WONG YJ, Teng M, Sim A, Thet HM, et al
Full adherence to cirrhosis quality indicators is associated with lower mortality in acute variceal bleeding: Nationwide audit.
Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000793.
PubMed Abstract available

HASSAN MM, Li D, Han Y, Byun J, et al
Genome-wide association study identifies high-impact susceptibility loci for hepatocellular carcinoma in North America.
Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000800.
PubMed Abstract available

ENGELSKIRCHER SA, Chen PC, Strunz B, Oltmanns C, et al
Impending hepatocellular carcinoma diagnosis in cirrhotic patients after HCV cure features a natural killer cell signature.
Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000804.
PubMed Abstract available

PENG Z, Wei G, Huang P, Matta H, et al
ASK1/p38 axis inhibition blocks the release of mitochondrial "danger signals" from hepatocytes and suppresses progression to cirrhosis and liver cancer.
Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000801.
PubMed Abstract available

HE B, Huang Z, Qin S, Peng P, et al
Enhanced SLC35B2/SAV1 sulfation axis promotes tumor growth through inhibiting Hippo signaling in hepatocellular carcinoma.
Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000783.
PubMed Abstract available

CALTHORPE L, Chiou SH, Rubin J, Huang CY, et al
A modified hospital frailty risk score for patients with cirrhosis undergoing abdominal operations.
Hepatology. 2024 Feb 19. doi: 10.1097/HEP.0000000000000794.
PubMed Abstract available

PREMKUMAR M, Kajal K, Izzy M, Sihag BK, et al
Reply to 'liver, heart, and kidney crosstalk in cirrhosis: POCUS is the focus".
Hepatology. 2024 Feb 16. doi: 10.1097/HEP.0000000000000792.
PubMed

PAPATHERODORIDIS G, Lampertico P
Hepatocellular carcinoma risk in HBeAg-positive chronic hepatitis B patients under long-term nucleos(t)ide analogue therapy: New insights from Asia.
Hepatology. 2024 Feb 16. doi: 10.1097/HEP.0000000000000796.
PubMed

ZHU M, Liu Z, Chen S, Luo Z, et al
Sintilimab plus bevacizumab combined with radiotherapy as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A multicenter, single-arm, phase 2 study.
Hepatology. 2024 Feb 15. doi: 10.1097/HEP.0000000000000776.
PubMed Abstract available

PARK JG, Roh PR, Kang MW, Cho SW, et al
Intrahepatic immunoglobulin a complex induces polarization of cancer-associated fibroblasts to matrix phenotypes in the tumor microenvironment of hepatocellular carcinoma.
Hepatology. 2024 Feb 15. doi: 10.1097/HEP.0000000000000772.
PubMed Abstract available

DONGELMANS E, Erler N, Adam R, Nadalin S, et al
Recent outcomes of liver transplantation for Budd Chiari Syndrome - a study of the European Liver Transplant Registry (ELTR) and affiliated centers.
Hepatology. 2024 Feb 15. doi: 10.1097/HEP.0000000000000778.
PubMed Abstract available

AGRAWAL D, Ariga KK
Liver, heart, and kidney crosstalk in cirrhosis: POCUS is the focus.
Hepatology. 2024 Feb 14. doi: 10.1097/HEP.0000000000000789.
PubMed

ALLEGRETTI AS, Patidar KR, Ma AT, Cullaro G, et al
From past to present to future: Terlipressin and hepatorenal syndrome-acute kidney injury.
Hepatology. 2024 Feb 14. doi: 10.1097/HEP.0000000000000790.
PubMed Abstract available

MOCTEZUMA-VELAZQUEZ C, Wong YJ, Montano-Loza AJ
Editorial: Promise and pitfalls of a natural killer cell signature for hepatocellular carcinoma detection in HCV patients with sustained virological response.
Hepatology. 2024 Feb 14. doi: 10.1097/HEP.0000000000000797.
PubMed

EHRENBAUER AF, Egge JFM, Gabriel MM, Tiede A, et al
Comparison of six tests for diagnosing minimal hepatic encephalopathy and predicting clinical outcome - A prospective, observational study.
Hepatology. 2024 Feb 13. doi: 10.1097/HEP.0000000000000770.
PubMed Abstract available

RINELLA ME, Castro Narro GE, Krag A, Terrault N, et al
Reply: 'From NAFLD to MASLD: Promise and pitfalls of a new definition' dagger.
Hepatology. 2024;79:E16-E17.
PubMed

CUSI K, Younossi Z, Roden M
From NAFLD to MASLD: Promise and pitfalls of a new definition dagger.
Hepatology. 2024;79:E13-E15.
PubMed

BALAKRISHNAN M, Rehm J
A public health perspective on mitigating the global burden of chronic liver disease.
Hepatology. 2024;79:451-459.
PubMed Abstract available

KHALID M, Khan ZM, Sheraz Kahloon A
Letter to the Editor: NAFLD improves risk prediction of type 2 diabetes-With effect modification by sex and menopausal status.
Hepatology. 2024;79:E18-E19.
PubMed

KIM Y, Chang Y, Ryu S, Wild SH, et al
Reply: NAFLD improves risk prediction of type 2 diabetes-With effect modification by sex and menopausal status.
Hepatology. 2024;79:E20-E21.
PubMed

BARR RG, Bolondi L
Contrast-enhanced US for HCC: Finally out from the waiting list?
Hepatology. 2024;79:267-268.
PubMed

LYSHCHIK A, Wessner CE, Bradigan K, Eisenbrey JR, et al
Contrast-enhanced ultrasound liver imaging reporting and data system: clinical validation in a prospective multinational study in North America and Europe.
Hepatology. 2024;79:380-391.
PubMed Abstract available

HUANG H, Tsui YM, Ho DW, Chung CY, et al
LANCL1, a cell surface protein, promotes liver tumor initiation through FAM49B-Rac1 axis to suppress oxidative stress.
Hepatology. 2024;79:323-340.
PubMed Abstract available

LAZARUS JV, Mark HE, Allen AM, Arab JP, et al
A global action agenda for turning the tide on fatty liver disease.
Hepatology. 2024;79:502-523.
PubMed Abstract available

MENG Z, Zhou L, Hong S, Qiu X, et al
Myeloid-specific ablation of Basp1 ameliorates diet-induced NASH in mice by attenuating pro-inflammatory signaling.
Hepatology. 2024;79:409-424.
PubMed Abstract available

SINHA S, Hassan N, Schwartz RE
Organelle stress and alterations in interorganelle crosstalk during liver fibrosis.
Hepatology. 2024;79:482-501.
PubMed Abstract available

Hepatology Highlights.
Hepatology. 2024;79:255-256.
PubMed

Hepatology Highlights.
Hepatology. 2024;79:255-256.
PubMed

January 2024

Erratum: Inhibition of microRNA-24 expression in liver prevents hepatic lipid accumulation and hyperlipidemia.
Hepatology. 2024 Jan 29. doi: 10.1097/HEP.0000000000000730.
PubMed

WANG Y, Wang X, Bai B, Shaha A, et al
Targeting Src SH3 domain-mediated glycolysis of hepatic stellate cells suppresses transcriptome, myofibroblastic activation, and colorectal liver metastasis.
Hepatology. 2024 Jan 24. doi: 10.1097/HEP.0000000000000763.
PubMed Abstract available

XIA Y, Wang Y, Xiong Q, He J, et al
Neutrophil extracellular traps promote MASH fibrosis by metabolic reprogramming of hepatic stellate cells.
Hepatology. 2024 Jan 24. doi: 10.1097/HEP.0000000000000762.
PubMed Abstract available

Hepatology highlights.
Hepatology. 2024 Jan 23. doi: 10.1097/HEP.0000000000000742.
PubMed

NAKAGAWA H, Lin A
The translation of oncogenic mRNAs regulated by pseudouridylation: A new player in hepatocellular carcinoma.
Hepatology. 2024 Jan 22. doi: 10.1097/HEP.0000000000000761.
PubMed

NIEMIETZ P, Peiseler M, Kohlhepp M, Horn P, et al
C-C chemokine receptor type 7 (CCR7) regulates hepatic CD8+ T cell homeostasis and response to acute liver injury.
Hepatology. 2024 Jan 17. doi: 10.1097/HEP.0000000000000757.
PubMed Abstract available

TRIPODI A, Primignani M, D'Ambrosio R, Tosetti G, et al
Reappraisal of the conventional hemostasis tests as predictors of perioperative bleeding in the era of rebalanced hemostasis in cirrhosis.
Hepatology. 2024 Jan 12. doi: 10.1097/HEP.0000000000000756.
PubMed Abstract available

Hepatology Highlights.
Hepatology. 2024;79:1-2.
PubMed

BARGELLINI I, Rimassa L, Masi G
SIRT and chemotherapy in unresectable iCCA: Ready to take off.
Hepatology. 2024;79:9-11.
PubMed

EMANUELE E, Minoretti P
Letter to the Editor: NAFLD, MAFLD or MASLD? Cut the Gordian knot with "Ludwig disease".
Hepatology. 2024;79:E4.
PubMed

NEWSOME P, Rinella ME, Lazarus JV, Terrault N, et al
Reply: NAFLD, MAFLD, or MASLD? Cut the Gordian knot with "Ludwig disease".
Hepatology. 2024;79:E5-E6.
PubMed

ROWE IA
Prediction of outcomes in patients with acute variceal bleeding.
Hepatology. 2024;79:15-17.
PubMed

WANG CC, Cheng YM, Kao JH
Letter to the Editor: Statement of steatotic liver disease-A great leap toward the global standardization.
Hepatology. 2024;79:E7-E8.
PubMed

GARCIA-CRIADO A, Bruix J
Screening for liver cancer: The good, the bad, and the ugly.
Hepatology. 2024;79:12-14.
PubMed

CORPECHOT C, Lemoinne S, Soret PA, Hansen B, et al
Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?
Hepatology. 2024;79:39-48.
PubMed Abstract available

LEE EW, Eghtesad B, Garcia-Tsao G, Haskal ZJ, et al
AASLD Practice Guidance on the use of TIPS, variceal embolization, and retrograde transvenous obliteration in the management of variceal hemorrhage.
Hepatology. 2024;79:224-250.
PubMed

Hepatology Highlights.
Hepatology. 2024;79:1-2.
PubMed

December 2023

HOFER BS, Brusilovskaya K, Simbrunner B, Balcar L, et al
Decreased platelet activation predicts hepatic decompensation and mortality in patients with cirrhosis.
Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000740.
PubMed Abstract available

VAJRO P, Mandato C
Letter to the Editor: More on Non-Alcohol/Non-Metabolic Dysfunction-Associated Steatohepatitis.
Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000734.
PubMed

JENG WJ, Chien RN, Liaw YF
Reply: Halting antiviral therapy in patients with cirrhosis and chronic hepatitis B: A dangerous game?
Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000737.
PubMed

CORPECHOT C, Lemoinne S, Soret PA, Chazouilleres O, et al
Reply: Improving access to transient elastography data for Real-World Prognostic Applications in primary biliary cholangitis.
Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000746.
PubMed

WIEGAND J, Franke A, Stein K, Trautwein C, et al
Letter to the Editor: Improving access to transient elastography data for real-world prognostic applications in primary biliary cholangitis.
Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000744.
PubMed

WATT KD, Khan MQ
Reply to "more on non-alcohol/non-metabolic dysfunction-associated steatohepatitis".
Hepatology. 2023 Dec 26. doi: 10.1097/HEP.0000000000000739.
PubMed

CHEN J, Tu T, Cohen C, Wang S, et al
Letter to the Editor: Halting antiviral therapy in patients with cirrhosis and chronic hepatitis B: A dangerous game?
Hepatology. 2023 Dec 26. doi: 10.1097/HEP.0000000000000732.
PubMed

ZABRANSKY DJ, Yarchoan M, Ho WJ
Reply: The Hepa 1-6 may not be suitable for use in hepatocellular carcinoma models to explore responses to drug therapy.
Hepatology. 2023 Dec 26. doi: 10.1097/HEP.0000000000000738.
PubMed

LU T, Zhang J, Li H, Li G, et al
Letter to the Editor: The Hepa 1-6 may not be suitable for use in hepatocellular carcinoma models to explore responses to drug therapy.
Hepatology. 2023 Dec 25. doi: 10.1097/HEP.0000000000000733.
PubMed

KREMER AE, Mayo MJ, Hirschfield GM, Levy C, et al
Seladelpar treatment reduces interleukin-31 and pruritus in patients with primary biliary cholangitis.
Hepatology. 2023 Dec 20. doi: 10.1097/HEP.0000000000000728.
PubMed Abstract available

RATZIU V, Francque S, Behling CA, Cejvanovic V, et al
Artificial intelligence scoring of liver biopsies in a phase ii trial of semaglutide in non-alcoholic steatohepatitis.
Hepatology. 2023 Dec 19. doi: 10.1097/HEP.0000000000000723.
PubMed Abstract available

VOGEL A, Grant RC, Meyer T, Sapisochin G, et al
Adjuvant and neoadjuvant therapies for hepatocellular carcinoma.
Hepatology. 2023 Dec 18. doi: 10.1097/HEP.0000000000000726.
PubMed Abstract available

SIDDIQUI MS, Muthiah M, Satapathy SK, Patidar K, et al
Defining an approach for therapeutic strategies in metabolic dysfunction-associated steatotic liver disease after liver transplantation.
Hepatology. 2023 Dec 13. doi: 10.1097/HEP.0000000000000720.
PubMed Abstract available

SCHULZE RJ, Strom SC, Nyberg SL
From pain to gain: Leveraging acetaminophen in hepatocyte transplantation for phenylketonuria.
Hepatology. 2023 Dec 12. doi: 10.1097/HEP.0000000000000713.
PubMed

YU S, Liu X, Xu Y, Pan L, et al
m6A-mediated gluconeogenic enzyme PCK1 upregulation protects against hepatic ischemia-reperfusion injury.
Hepatology. 2023 Dec 12. doi: 10.1097/HEP.0000000000000716.
PubMed Abstract available

YIN C, Zhang C, Wang Y, Liu G, et al
ALDOB/KAT2A interactions epigenetically modulate TGF-beta expression and T cell functions in hepatocellular carcinogenesis.
Hepatology. 2023 Dec 5. doi: 10.1097/HEP.0000000000000704.
PubMed Abstract available

CHAN FF, Yuen VW, Shen J, Chin DW, et al
Inhibition of CAF-1 histone chaperone complex triggers cytosolic DNA and dsRNA sensing pathways and induces intrinsic immunity of hepatocellular carcinoma.
Hepatology. 2023 Dec 5. doi: 10.1097/HEP.0000000000000709.
PubMed Abstract available

MALHI H, Brown RS Jr, Lim JK, Reau N, et al
Precipitous changes in nomenclature and definitions-NAFLD becomes SLD: Implications for and expectations of AASLD journals.
Hepatology. 2023;78:1680-1681.
PubMed

RINELLA ME, Lazarus JV, Ratziu V, Francque SM, et al
A multisociety Delphi consensus statement on new fatty liver disease nomenclature.
Hepatology. 2023;78:1966-1986.
PubMed Abstract available

DESAI AP, Madathanapalli A, Tang Q, Orman ES, et al
PROMIS Profile-29 is a valid instrument with distinct advantages over legacy instruments for measuring the quality of life in chronic liver disease.
Hepatology. 2023;78:1788-1799.
PubMed Abstract available

ABERG F
Letter to the Editor: ELF in the risk stratification of NAFLD-Are the ELF thresholds suggested by the AASLD guidelines appropriate?
Hepatology. 2023;78:E101-E102.
PubMed

RINELLA ME, Terrault N, Neuschwander-Tetri B, Loomba R, et al
Reply: ELF in the risk stratification of NAFLD-Are the ELF thresholds suggested by the AASLD guidelines appropriate?
Hepatology. 2023;78:E103-E104.
PubMed

ZHANG X, Yip TC, Tse YK, Hui VW, et al
Duration of type 2 diabetes and liver-related events in nonalcoholic fatty liver disease: A landmark analysis.
Hepatology. 2023;78:1816-1827.
PubMed Abstract available

GAO R, Li Y, Xu Z, Zhang F, et al
Mitochondrial pyruvate carrier 1 regulates fatty acid synthase lactylation and mediates treatment of nonalcoholic fatty liver disease.
Hepatology. 2023;78:1800-1815.
PubMed Abstract available

Erratum: Interleukin-18 signaling promotes activation of hepatic stellate cells in mouse liver fibrosis.
Hepatology. 2023;78:E110.
PubMed

Erratum: Diabetes and cirrhosis: Current concepts on diagnosis and management.
Hepatology. 2023;78:E108.
PubMed

Erratum: Inhibition of mPGES-2 ameliorates non-alcoholic steatohepatitis by activating NR1D1 via heme.
Hepatology. 2023;78:E107.
PubMed

MAIWALL R, Piano S, Singh V, Caraceni P, et al
Determinants of clinical response to empirical antibiotic treatment in patients with cirrhosis and bacterial and fungal infections- Results from the ICA 'Global study' [EABCIR-Global Study].
Hepatology. 2023 Dec 1. doi: 10.1097/HEP.0000000000000653.
PubMed Abstract available

Ending stigmatizing language in alcohol and liver disease: A liver societies' statement dagger.
Hepatology. 2023;78:1682-1683.
PubMed

November 2023

HU YX, Diao LT, Hou YR, Lv G, et al
PUS1 promotes hepatocellular carcinoma via mRNA pseudouridylation to enhance the translation of oncogenic mRNAs.
Hepatology. 2023 Nov 28. doi: 10.1097/HEP.0000000000000702.
PubMed Abstract available

PREMKUMAR M, Kajal K, Reddy KR, Izzy M, et al
Evaluation of terlipressin-related patient outcomes in hepatorenal syndrome-acute kidney injury using point-of-care echocardiography.
Hepatology. 2023 Nov 17. doi: 10.1097/HEP.0000000000000691.
PubMed Abstract available

MICHALOPOULOS GK
Hepatocytes of mice and men: Different regenerative signals?
Hepatology. 2023 Nov 16. doi: 10.1097/HEP.0000000000000693.
PubMed

KE L, Rui Z, Fukai W, Yunzheng Z, et al
Single-cell dissection of the multicellular ecosystem and molecular features underlying microvascular invasion in hepatocellular carcinoma.
Hepatology. 2023 Nov 16. doi: 10.1097/HEP.0000000000000673.
PubMed Abstract available

February 2024 Hepatology Highlights.
Hepatology. 2023 Nov 16. doi: 10.1097/HEP.0000000000000681.
PubMed

VAN DER MEEREN PE, Frederik de Wilde R, Sprengers D, IJzermans JNM, et al
Benefit and harm of waiting time in liver transplantation for HCC.
Hepatology. 2023 Nov 16. doi: 10.1097/HEP.0000000000000668.
PubMed Abstract available

LIU N, Tian J, Steer CJ, Han Q, et al
MicroRNA-206-3p suppresses hepatic lipogenesis and cholesterol synthesis while driving cholesterol efflux.
Hepatology. 2023 Nov 9. doi: 10.1097/HEP.0000000000000672.
PubMed Abstract available

KARVELLAS CJ, Bajaj JS, Kamath PS, Napolitano L, et al
AASLD Practice guidance on Acute-on-chronic liver failure and the management of critically Ill patients with cirrhosis.
Hepatology. 2023 Nov 9. doi: 10.1097/HEP.0000000000000671.
PubMed

QASIM KHAN M, Hassan S, Lizaola-Mayo BC, Bhat M, et al
Navigating the 'Specific Etiology' steatohepatitis category: Evaluation & management of non-alcohol/non-metabolic dysfunction-associated steatohepatitis.
Hepatology. 2023 Nov 7. doi: 10.1097/HEP.0000000000000674.
PubMed

BRENNER DA
Alternatives to animal testing to assess NASH drugs and hepatotoxicity.
Hepatology. 2023 Nov 6. doi: 10.1097/HEP.0000000000000669.
PubMed Abstract available

SCHERR AL, Nader L, Xu K, Elssner C, et al
Etiology-independent activation of the LTbeta-LTbetaR-RELB axis drives aggressiveness and predicts poor prognosis in Hepatocellular carcinoma.
Hepatology. 2023 Nov 2. doi: 10.1097/HEP.0000000000000657.
PubMed Abstract available

D'AMICO G, Zipprich A, Villanueva C, Sorda JA, et al
Further decompensation in cirrhosis. Results of a large multicenter cohort study supporting Baveno VII statements.
Hepatology. 2023 Nov 2. doi: 10.1097/HEP.0000000000000652.
PubMed Abstract available

RINELLA ME, Terrault N, Neuschwander-Tetri B, Loomba R, et al
Reply: People living with HIV and NAFLD and updated guidance on NAFLD screening.
Hepatology. 2023;78:E91-E92.
PubMed

ARIAS-LOSTE MT, Crespo J, Iruzubieta P
Letter to the Editor: Updated guidance on NAFLD screening.
Hepatology. 2023;78:E89-E90.
PubMed

SEBASTIANI G, Milic J, Tsochatzis EA, Marzolini C, et al
Letter to the Editor: People living with HIV and NAFLD-A population left behind in the global effort for liver fibrosis screening?
Hepatology. 2023;78:E87-E88.
PubMed

YANG Z, Ding WX
The pre-mRNA alternative splicing regulated by SRPK2: A new player in alcohol-associated liver disease?
Hepatology. 2023;78:1329-1331.
PubMed

LAZARUS JV, Kopka CJ, Younossi ZM, Allen AM, et al
It is time to expand the fatty liver disease community of practice.
Hepatology. 2023;78:1325-1328.
PubMed

TILG H, Adolph TE, Tacke F
Therapeutic modulation of the liver immune microenvironment.
Hepatology. 2023;78:1581-1601.
PubMed Abstract available

NIKNEJAD N, Fox D, Burwinkel JL, Zarrin-Khameh N, et al
ASO silencing of a glycosyltransferase, Poglut1 , improves the liver phenotypes in mouse models of Alagille syndrome.
Hepatology. 2023;78:1337-1351.
PubMed Abstract available

WU Q, Pan C, Zhou Y, Wang S, et al
Targeting neuropilin-1 abolishes anti-PD-1-upregulated regulatory T cells and synergizes with 4-1BB agonist for liver cancer treatment.
Hepatology. 2023;78:1402-1417.
PubMed Abstract available

SONG Y, Wei J, Li R, Fu R, et al
Tyrosine kinase receptor B attenuates liver fibrosis by inhibiting TGF-beta/SMAD signaling.
Hepatology. 2023;78:1433-1447.
PubMed Abstract available

CHIU YT, Husain A, Sze KM, Ho DW, et al
Midline 1 interacting protein 1 promotes cancer metastasis through FOS-like 1-mediated matrix metalloproteinase 9 signaling in HCC.
Hepatology. 2023;78:1368-1383.
PubMed Abstract available

YANG F, Hilakivi-Clarke L, Shaha A, Wang Y, et al
Metabolic reprogramming and its clinical implication for liver cancer.
Hepatology. 2023;78:1602-1624.
PubMed Abstract available

LEE CM, Yoon EL, Kim M, Kang BK, et al
Prevalence, distribution and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings.
Hepatology. 2023 Nov 1. doi: 10.1097/HEP.0000000000000664.
PubMed Abstract available

BRAILLON A, Naudet F
Letter to the Editor: Medications promoting abstinence in alcohol-associated cirrhosis.
Hepatology. 2023 Nov 1. doi: 10.1097/HEP.0000000000000656.
PubMed

October 2023

JENG WJ, Chien RN, Liaw YF
Reply: Cautious interpretation of the association between finite treatment and better prognosis in initially HBeAg-negative hepatitis B patients with cirrhosis.
Hepatology. 2023 Oct 31. doi: 10.1097/HEP.0000000000000662.
PubMed

DENG R, Wang Z, Liu Y, Sun J, et al
Letter to the Editor: Cautious interpretation of the association between finite treatment and better prognosis in initially HBeAg-negative hepatitis B patients with cirrhosis.
Hepatology. 2023 Oct 31. doi: 10.1097/HEP.0000000000000654.
PubMed

GRATACOS-GINES J, Lopez-Pelayo H, Pose E
Reply: Medications promoting abstinence in alcohol-associated cirrhosis.
Hepatology. 2023 Oct 31. doi: 10.1097/HEP.0000000000000660.
PubMed

SELLERS ZM, Assis DN, Paranjape SM, Sathe M, et al
Cystic fibrosis screening, evaluation and management of hepatobiliary disease consensus recommendations.
Hepatology. 2023 Oct 26. doi: 10.1097/HEP.0000000000000646.
PubMed Abstract available

SONG Y, Ye T, Roberts LR, Larson NB, et al
Randomization in hepatology: A review of principles, opportunities, and challenges.
Hepatology. 2023 Oct 24. doi: 10.1097/HEP.0000000000000649.
PubMed Abstract available

KAPLAN DE, Bosch J, Ripoll C, Thiele M, et al
AASLD practice guidance on risk stratification and management of portal hypertension and varices in cirrhosis.
Hepatology. 2023 Oct 23. doi: 10.1097/HEP.0000000000000647.
PubMed

YANG T, Qu X, Wang X, Xu D, et al
Macrophage STING-YAP axis controls hepatic steatosis by promoting autophagic degradation of lipid droplets.
Hepatology. 2023 Oct 23. doi: 10.1097/HEP.0000000000000638.
PubMed Abstract available

CHANG CW, Chen YS, Huang CH, Lin CH, et al
A genetic basis of mitochondrial DNAJA3 in nonalcoholic steatohepatitis-related hepatocellular carcinoma.
Hepatology. 2023 Oct 23. doi: 10.1097/HEP.0000000000000637.
PubMed Abstract available

OLIVA-VILARNAU N, Beusch CM, Sabatier P, Sakaraki E, et al
Wnt/beta-catenin and NFkappaB signaling synergize to trigger growth-factor-free regeneration of adult primary human hepatocytes.
Hepatology. 2023 Oct 23. doi: 10.1097/HEP.0000000000000648.
PubMed Abstract available

CAMPANI C, Vallot A, Ghannouchi H, Allaire M, et al
Impact of radiological response and pattern of progression in patients with hepatocellular carcinoma treated by atezolizumab- bevacizumab.
Hepatology. 2023 Oct 23. doi: 10.1097/HEP.0000000000000636.
PubMed Abstract available

GISH RG, Wong RJ, Di Tanna GL, Kaushik A, et al
Association between hepatitis delta virus with liver morbidity and mortality: A systematic literature review and meta-analysis.
Hepatology. 2023 Oct 23. doi: 10.1097/HEP.0000000000000642.
PubMed Abstract available

DONGELMANS EJ, Sonneveld MJ, Janssen HLA
Letter to the Editor: Benefits of stopping therapy in cirrhotic hepatitis B patients, true effect or residual confounding?
Hepatology. 2023 Oct 20. doi: 10.1097/HEP.0000000000000639.
PubMed

LIAW YF, Jeng WJ, Chien RN
Reply: Benefits of stopping therapy in cirrhotic hepatitis B patients, true effect or residual confounding?
Hepatology. 2023 Oct 20. doi: 10.1097/HEP.0000000000000641.
PubMed

Erratum: AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma.
Hepatology. 2023 Oct 16. doi: 10.1097/HEP.0000000000000621.
PubMed

VONADA A, Wakefield L, Martinez M, Harding CO, et al
Complete correction of murine phenylketonuria by selection-enhanced hepatocyte transplantation.
Hepatology. 2023 Oct 12. doi: 10.1097/HEP.0000000000000631.
PubMed Abstract available

CHEN P, Dong Z, Zhu W, Chen J, et al
Noncanonical regulation of HOIL-1 on cancer stemness and sorafenib resistance identifies pixantrone as a novel therapeutic agent for hepatocellular carcinoma.
Hepatology. 2023 Oct 11. doi: 10.1097/HEP.0000000000000623.
PubMed Abstract available

MA S, Chew V
Unlocking the immune microenvironment of non-alcoholic steatohepatitis-associated hepatocellular carcinoma.
Hepatology. 2023 Oct 9. doi: 10.1097/HEP.0000000000000626.
PubMed

THIELE M, Johansen S, Israelsen M, Trebicka J, et al
Non-invasive assessment of hepatic decompensation.
Hepatology. 2023 Oct 6. doi: 10.1097/HEP.0000000000000618.
PubMed Abstract available

PENNISI G, Enea M, Romero-Gomez M, Bugianesi E, et al
Risk of liver-related events in metabolic dysfunction-associated steatohepatitis (MASH) patients with fibrosis: A comparative analysis of various risk stratification criteria.
Hepatology. 2023 Oct 2. doi: 10.1097/HEP.0000000000000616.
PubMed Abstract available

XANTHAKOS S
Rising tide of NAFLD in youth: A warning bell and call to action.
Hepatology. 2023;78:1017-1019.
PubMed

ANTON A, Shalaby S, Hernandez-Gea V
Coagulation meets senescence in NASH!
Hepatology. 2023;78:1023-1025.
PubMed

YONEDA M, Nakajima A
The role of MRI technology in liver evaluation for NAFLD patients: Advancements and opportunities.
Hepatology. 2023;78:1020-1022.
PubMed

CHEN W, Sun Y, Chen S, Ge X, et al
Matrisome gene-based subclassification of patients with liver fibrosis identifies clinical and molecular heterogeneities.
Hepatology. 2023;78:1118-1132.
PubMed Abstract available

LI J, Lu X, Zhu Z, Kalutkiewicz KJ, et al
Head-to-head comparison of magnetic resonance elastography-based liver stiffness, fat fraction, and T1 relaxation time in identifying at-risk NASH.
Hepatology. 2023;78:1200-1208.
PubMed Abstract available

KIM ??? WR, Iwakiri ???? Y, Lok ??? ASF
What is in a name? Toward culturally sensitive nomenclature for liver disease in the east and west.
Hepatology. 2023;78:1032-1034.
PubMed

MINCIUNA I, Gallage S, Heikenwalder M, Zelber-Sagi S, et al
Intermittent fasting-the future treatment in NASH patients?
Hepatology. 2023;78:1290-1305.
PubMed Abstract available

CALZADILLA-BERTOT L, Jeffrey GP, Wang Z, Huang Y, et al
Predicting liver-related events in NAFLD: A predictive model.
Hepatology. 2023;78:1240-1251.
PubMed Abstract available

SEIMIYA T, Otsuka M, Fujishiro M
Overcoming T-cell exhaustion: New therapeutic targets in HCC immunotherapy.
Hepatology. 2023;78:1009-1011.
PubMed

Erratum: Down-Regulation of the Cyclin-Dependent kinase inhibitor p57 is mediated by Jab1/Csn5 in hepatocarcinogenesis.
Hepatology. 2023;78:E85.
PubMed

STRAVITZ RT, Fontana RJ, Karvellas C, Durkalski V, et al
Future directions in acute liver failure.
Hepatology. 2023;78:1266-1289.
PubMed Abstract available

HARTMANN P, Zhang X, Loomba R, Schnabl B, et al
Global and national prevalence of nonalcoholic fatty liver disease in adolescents: An analysis of the global burden of disease study 2019.
Hepatology. 2023;78:1168-1181.
PubMed Abstract available

KOTULKAR M, Paine-Cabrera D, Abernathy S, Robarts DR, et al
Role of HNF4alpha-cMyc interaction in liver regeneration and recovery after acetaminophen-induced acute liver injury.
Hepatology. 2023;78:1106-1117.
PubMed Abstract available

DE ANGELIS RIGOTTI F, Wiedmann L, Hubert MO, Vacca M, et al
Semaphorin 3C exacerbates liver fibrosis.
Hepatology. 2023;78:1092-1105.
PubMed Abstract available

September 2023

NAHON P, Layese R, Ganne-Carrie N, Moins C, et al
The clinical and financial burden of nonhepatocellular carcinoma focal lesions detected during surveillance of patients with cirrhosis.
Hepatology. 2023 Sep 29. doi: 10.1097/HEP.0000000000000615.
PubMed Abstract available

LI M, Wang L, Cong L, Wong CC, et al
Spatial proteomics of immune microenvironment in nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
Hepatology. 2023 Sep 21. doi: 10.1097/HEP.0000000000000591.
PubMed Abstract available

RINELLA ME, Lieu HD, Kowdley KV, Goodman ZD, et al
A randomized, double-blind, placebo-controlled trial of Aldafermin in patients with nonalcoholic steatohepatitis and compensated cirrhosis.
Hepatology. 2023 Sep 21. doi: 10.1097/HEP.0000000000000607.
PubMed Abstract available

ZHAO X, Kotha S, Nayyar D, Ma X, et al
Physiologic changes in the hepatopulmonary syndrome before and after liver transplant: A longitudinal and predictor analysis.
Hepatology. 2023 Sep 21. doi: 10.1097/HEP.0000000000000605.
PubMed Abstract available

FAILLI M, Demir S, Del Rio-Alvarez A, Carrillo-Reixach J, et al
Computational drug prediction in hepatoblastoma by integrating pan-cancer transcriptomics with pharmacological response.
Hepatology. 2023 Sep 20. doi: 10.1097/HEP.0000000000000601.
PubMed Abstract available

GELLERT-KRISTENSEN H, Bojesen SE, Tybjaerg-Hansen A, Stender S, et al
Telomere length and risk of cirrhosis, hepatocellular carcinoma, and cholangiocarcinoma in 63,272 individuals from the general population.
Hepatology. 2023 Sep 19. doi: 10.1097/HEP.0000000000000608.
PubMed Abstract available

WATT KD, Paul S, Khan MQ, Siddiqui M, et al
Obesity management for the hepatologist - what to do, how to do it and why.
Hepatology. 2023 Sep 19. doi: 10.1097/HEP.0000000000000598.
PubMed Abstract available

CHEN S, Liao C, Hu H, Liao J, et al
Hypoxia-driven tumor stromal remodeling and immunosuppressive microenvironment in scirrhous hepatocellular carcinoma.
Hepatology. 2023 Sep 19. doi: 10.1097/HEP.0000000000000599.
PubMed Abstract available

MAESTRI E, Kedei N, Khatib S, Forgues M, et al
Spatial proximity of Tumor-Immune interactions predicts patient outcome in hepatocellular carcinoma.
Hepatology. 2023 Sep 19. doi: 10.1097/HEP.0000000000000600.
PubMed Abstract available

ZHUANG Y, Ortega-Ribera M, Thevkar Nagesh P, Joshi R, et al
Bile acid-induced IRF3 phosphorylation mediates cell death, inflammatory responses and fibrosis in cholestasis-induced liver and kidney injury via regulation of ZBP1.
Hepatology. 2023 Sep 19. doi: 10.1097/HEP.0000000000000611.
PubMed Abstract available

December 2023 Hepatology Highlights.
Hepatology. 2023 Sep 14. doi: 10.1097/HEP.0000000000000594.
PubMed

WU T, Chen X, Xu K, Dai C, et al
LIM domain only 7 negatively controls non-alcoholic steatohepatitis in the setting of hyperlipidaemia.
Hepatology. 2023 Sep 1. doi: 10.1097/HEP.0000000000000585.
PubMed Abstract available

August 2023

GE J, Fontil V, Ackerman S, Pletcher MJ, et al
Clinical decision support and electronic interventions to improve care quality in chronic liver diseases and cirrhosis.
Hepatology. 2023 Aug 23. doi: 10.1097/HEP.0000000000000583.
PubMed Abstract available

PEISELER M, Tacke F
Bile duct-associated macrophages enter the spotlight in inflammatory cholestatic liver disease.
Hepatology. 2023 Aug 22. doi: 10.1097/HEP.0000000000000576.
PubMed

BOWLUS CL, Levy C
Optimizing treatment of primary biliary cholangitis: Is good, good enough?
Hepatology. 2023 Aug 2. doi: 10.1097/HEP.0000000000000556.
PubMed

DE MUYNCK K, Heyerick L, De Ponti FF, Vanderborght B, et al
Osteopontin characterizes bile duct associated macrophages and correlates with liver fibrosis severity in primary sclerosing cholangitis.
Hepatology. 2023 Aug 2. doi: 10.1097/HEP.0000000000000557.
PubMed Abstract available

August Hepatology Highlights.
Hepatology. 2023;78:369-370.
PubMed

July 2023

July 2023 Hepatology Highlights.
Hepatology. 2023;78:1-2.
PubMed

June 2023

SOKOL RJ, Gonzales EM, Kamath BM, Baker A, et al
Predictors of 6-year event-free survival in alagille syndrome patients treated with maralixibat, an ileal bile acid transporter inhibitor.
Hepatology. 2023 Jun 7. doi: 10.1097/HEP.0000000000000502.
PubMed Abstract available

May 2023

May 2023 Hepatology Highlights.
Hepatology. 2023;77:1461-1462.
PubMed

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge.

Privacy / Datenschutzerklärung | Imprint / Impressum